胡椒碱对姜黄素代谢和调脂效应的影响
|
摘要
高脂血症是人体脂质代谢失常导致血浆内脂质浓度超过正常范围的病症,是引发动脉粥样硬化、冠心病及高血压的主要危险因素。近年来,高脂血症的发病率呈不断上升的趋势,多数降脂药仅有短期疗效,长期使用则会出现明显的毒副反应。辨证论治、因人、因时、因地制宜的个体化治疗体系是中医的诊治特点,中药通过多环节、多层次、多靶点的整合调节作用,符合人体多样性的特点。故从中药、天然药物中寻找安全有效的调脂药物是目前发展的趋势。姜黄素所具有的降血脂、抗突变、抗氧化、清除自由基等药理作用,使其成为在治疗高脂血症方面较有发展前途的药物。但是,姜黄素本身存在的一些问题,例如脂溶性高、水中溶解度小、稳定性差、在肝脏和肠道内易分解转化等,导致其口服血药浓度低、生物利用度差、用药量大,从而大大限制了临床推广使用和新药的开发。针对这些问题,本课题将姜黄素与已知的肝、肠内葡萄糖醛酸转移酶抑制剂-胡椒碱合用,通过抑制肝肠内姜黄素的葡萄糖醛酸化,从而减少姜黄素的代谢;并采用微囊化技术,以增加其稳定性和水溶性,促进其吸收,减少服用次数,维持持久药效,以提高生物利用度。本课题的主要研究内容如下:
研究目的:
本课题以期寻找姜黄素与胡椒碱最佳组方比例;探讨通过微囊化工艺改进后,姜黄素在动物体内的药代动力学过程,以及加入胡椒碱后对姜黄素药代动力学过程的影响;考察姜黄素和胡椒碱组方-复方姜黄微囊的调脂效应,并与单独应用姜黄素相比,加入胡椒碱后对姜黄素的调脂作用的影响。以期解决一直围绕姜黄素水溶性差、稳定性不好、易分解代谢、药理活性低等问题,最大的发挥姜黄素的调脂效应,为姜黄素和胡椒碱组方提供佐证,并为将复方姜黄微囊开发为安全、有效调脂新药打下基础。
研究方法:
①通过传代培养复制Caco-2细胞模型;采用“门静脉二步灌流分离法”进行正常和高脂血症模型大鼠肝脏原位灌流,然后进行悬浮培养建立原代肝细胞模型。进行细胞活性评定后,开展药物细胞毒性实验,计算最大无毒浓度,由此确定药效实验最大给药剂量。然后以与姜黄素肝肠内代谢密切相关的β-GD为观察指标,观察姜黄素与胡椒碱不同比例降低β-GD活性的差异。通过尾静脉注射Triton WR-1339 250mg/kg复制急性小鼠高脂血症模型,考察姜黄素与胡椒碱不同比例的调脂效应,以期确定姜黄素与胡椒碱组方的最佳比例。
②通过灌胃给予不同剂量的姜黄素微囊制剂,用HPLC测定血浆和胆汁中姜黄素的含量,用DAS2.1软件计算结果,分析姜黄素微囊在大鼠体内的药动学过程。并考察姜黄素与胡椒碱为9:1、36:1和144:1时组方-复方姜黄微囊的大鼠体内药动学过程,以及评价胡椒碱对姜黄素药代动力学过程的影响。
③将动物分为空白对照组、模型对照组、阳性药物组、复方姜黄微囊高剂量组、复方姜黄微囊低剂量组、姜黄素高剂量组和姜黄素低剂量组。通过尾静脉注射TritonWR-1339复制急性小鼠高脂血症模型,和灌服高脂乳剂复制慢性食饵性大鼠高脂血症模型,检测动物血清、肝脏组织、粪便和胆汁中脂质、脂肪代谢酶、胆汁酸、载脂蛋白等成分的含量,对姜黄素和胡椒碱组方的调脂效应进行评价。同时与单独应用姜黄素进行比较,探讨胡椒碱对姜黄素调脂效应的影响。
研究结果:
①Caco-2细胞在3-5天内处于对数增殖期,故选择3-5天时的细胞进行药效研究。药物细胞毒性实验研究结果显示,胡椒碱TC_(50)=1.74mmol/L,TC_1=0.084 mmol/L,姜黄素TC_(50)=10.7mmol/L,TC_1=0.25mmol/L,TC_0=0.266 mmol/L,故姜黄素和胡椒碱分别以0.266mmol/L和0.084 mmol/L为药理实验研究的最大给药浓度。
②与细胞对照组相比,在1h和3h时,姜黄素与胡椒碱组方在8:1-33:1之间均有显著降低肝细胞内β-GD活性的作用;姜黄素与胡椒碱组方在8:1-65:1之间均有显著降低Caco-2细胞内β-GD活性的作用。
③与模型组比较,姜黄素与胡椒碱配比C组、配比D组和配比E组(10.4:1-41.6:1)均明显降低小鼠血清TC含量(P＜0.05-0.01);配比D组和配比E组(20.8:1-41.6:1)也明显降低小鼠血清TG含量(P＜0.01)。单独应用姜黄素有明显降低TC含量的作用(P＜0.05);单独应用胡椒碱没有显著性降低TC和TG水平的作用(P＞0.05)。其中配比E组(41.6:1)对TC和TG的抑制率为最高。通过聚类分析发现配比D组(20.8:1)和配比E组抑制TC和TG含量的百分率属同一类,即抑制效应无显著性差异。故在相同抑制效应情况下,应选择药物剂量小即配比D组作为药效实验的最佳配比剂量。
④确定了分别用乙酸乙酯和酸分解法萃取血浆和胆汁中姜黄素的方法;精密度、稳定性和加样回收率等方面的研究结果提示所建立的方法符合生物样品检测的要求。
⑤姜黄素微囊口服制剂在大鼠体内的代谢过程出现双峰现象。姜黄素高、中、低剂量的Cmax分别为1.16、0.55、2.66 mg/L;Tmax分别为1.5、1.1和0.78h;AUC分别为3.79、2.60和5.92。由此可见,姜黄素的药动学符合非线性过程,低剂量AUC和Cmax明显比高、中剂量高。与姜黄素脂质体和混悬液相比,本室制备的姜黄素微囊制剂低剂量以58.6mg/kg灌胃给药,将姜黄素的峰浓度提高到2.66mg/L,分别是姜黄素混悬液和脂质体的5.78和5.02倍;姜黄素微囊的AUC提高到5.92 mg·h/L,分别为姜黄素混悬液和脂质体的7.6倍和8.4倍,说明姜黄素微囊制剂明显提高了血药浓度和生物利用度。
⑥对姜黄素和胡椒碱不同比例组成的复方进行了药动学研究,胡椒碱为姜黄素1/9、1/36、1/144和单独应用姜黄素时,Cmax分别为3.45、4.14、2.43、2.23 mg/L:Tmax分别为2、3、1.05、0.75h;AUC分别为13.47、16.49、8.7、8.07。由此可见,加入胡椒碱后,Cmax和AUC明显升高,Tmax延长,尤其以姜黄素:胡椒碱=36:1的Cmax和AUC升高最明显。其Cmax为4.14mg/L,分别是姜黄素混悬液和姜黄素脂质体的9倍和7.8倍;AUC为16.49 mg·h/L,分别是姜黄素混悬液和姜黄素脂质体的21倍和23.6倍。
⑦姜黄素单独应用对血清、肝脏和粪便中脂质(TC、TG)含量均有降低作用,揭示姜黄素具有一定的降脂效应;但对血清和肝脏中脂质(HDL-C和LDL-C)含量无显著性影响;对胆汁和粪便中胆汁酸、脂肪代谢酶和载脂蛋白也无显著性影响。
⑧姜黄素与胡椒碱以20:1组成的复方姜黄微囊有明显降低血清、肝脏中脂质(TC、TG和LDL-C)和升高HDL-C含量的作用;还有促进胆汁和粪便中TC、TG和胆汁酸分泌和排泄的作用;增强血液载脂蛋白(apoAI、apoB及apoAI/apoB)活性的作用;增强血液和肝脏脂质代谢酶(LPL、HL、LCAT)的活性;此外,还有增强抗脂质过氧化酶(SOD和GSH-PX)的活性等作用。
⑨与单独应用姜黄素相比,复方姜黄素微囊在降低血液和肝脏中脂质含量;促进胆汁和粪便中TC、TG、胆汁酸排泄:增强载脂蛋白、脂质代谢酶和抗脂质过氧化酶的活性等方面有显著性差异。
研究结论:
①通过离体细胞实验的研究,并结合以高脂血症小鼠为模型开展的姜黄素与胡椒碱配比筛选结果,认为20:1是姜黄素与胡椒碱的最佳配比。
②建立了稳定的血浆和胆汁中姜黄素的HPLC检测方法。姜黄素微囊口服制剂在大鼠体内的药代动力学符合非线性过程。在血浆中的姜黄素药时曲线呈双峰现象,可能存在肝肠循环;也可能是因为姜黄素快速分布到其他组织,再次吸收入血导致第二个峰的出现,具体原因尚需进一步研究证实。低剂量的AUC和Cmax明显比高、中剂量高,可能是因为低剂量最接近临床拟用量和动物药效剂量,所以更易吸收入血。
③与姜黄素脂质体和混悬液相比,本室制备的姜黄素微囊制剂明显提高了血药浓度和生物利用度。与单独应用姜黄素相比,加入胡椒碱后姜黄素的血药浓度和生物利用度明显提高,提示胡椒碱作为肝肠内葡萄糖醛酸苷酶结合抑制剂,可能通过抑制肝肠内姜黄素的葡萄糖醛酸化,提高了姜黄素的生物利用度。通过开展本研究,可望为其新制剂的设计和临床合理用药提供参考。
④复方姜黄微囊对高脂血症小鼠模型和慢性食饵性高脂血症大鼠模型均有显著调脂作用;与单独应用姜黄素相比,复方姜黄素微囊的综合调脂效应明显强于单独应用姜黄素。
⑤复方姜黄微囊调脂作用可能与以下几点有关:(1)抑制肠道外源性脂质吸收,增加粪便中脂质(胆固醇和胆汁酸)含量,促进脂质排泄;(2)增强血液载脂蛋白(apoAI、apoB及apoAI/apoB)和脂肪酶(LPL、HL、LCAT)活性,促进血脂转化,加速血液TC和TG的代谢及脂质肝脏转运;(3)增强肝脏脂质代谢酶活性,加速肝脏对TC、TG代谢,增加胆汁分泌及胆汁中TC含量;(4)通过增强抗脂质过氧化能力(SOD和GSH-PX),抑制脂质过氧化;(5)通过降低血液与肝脏脂质含量,抑制肝脏脂肪样病变。
通过本课题的研究,为姜黄素和胡椒碱组方提供了实验依据,并验证了复方姜黄微囊有明确的调脂效应,提示复方姜黄微囊可能是一种有发展前景的有效调脂新药,以期为降脂中药新药的研发提供参考,探索出一套适合于中药新药研究的新思路和方法。
Hyperlipidemia,a disease of disorder of lipid metabolism in human,leads to the fact that plasma lipid concentrations exceed the normal range.Therefore,It is the major factor that causes atherosclerosis,coronary heart disease and high blood pressure.However,in recent years,the incidence of hyperlipidemia has been rising increasingly,and most of the lipid lowering drugs have only short-term efficacy,while Long-term use will result in toxicity.Therefore,to find safe and effective lipid lowering drugs from the traditional Chinese and natural medicine is the present trend for the treatment of the Hyperlipidemia. On one hand,the traditional Chinese medical diagnosis and treatment is characterized by its dialectic,which means,more specifically,an individual treatment basing on the patient,the time of the illness as well as the place where the treatment is implemented.On the other hand,the traditional Chinese medicine could integrate all its regulatory function through multi-links,multi-levels,multi-targets,which is in accordance with the diversity in human body.Curcumin has lots of pharmacological functions,such as curing hypolipidemic, anti-mutagenic,anti-oxidation,scavenging free radicals,which renders it to become more promising than other drugs in the treatment of hyperlipidemia.However,curcumin itself has a number of problems,such as high-fat-soluble,small water solubility,poor stability, easy decomposition and transformation in the liver and intestine,resulting in low serum concentration,poor bioavailability and large doses,which greatly limit its clinical use and the development of new drugs.To solve these problems,the dissertation combines curcumin with piperine,the glucuronosyltransferase inhibitors of liver and intestinal.By inhibiting the glucuronic acid of curcumin,the metabolism of curcumin will be reduced; and the use of micro - capsule technology will increase its stability and water-soluble, promote its absorption,reduce the frequency of use,and maintain a lasting effect;all the above will enhance its bioavailability.The main research topics of the dissertation are as follows:
Objective:
The dissertation firstly tries to explore the changes of the pharmacokinetics process of curcumin in rats after the technical improvement through the microcapsules as well as the effect after adding the piperine.Basing on the above experiment,the author manages to find the best set of square ratio of curcumin with piperine;Then,the author also studies the blood lipid regulating effects of Fufang Jianghuang microcystis,a Chinese medicine whose main ingredient is curcumin and piperine and compares the blood lipid regulating effects after the adding of piperine.Finally,The dissertation tries to solve those disadvantages of Curcumin,such an small water solubility,poor stability,easy decomposition and transformation and the low pharmacological activity,so as to realize the full play of the lipid effects of curcumin,to provide support for curcumin and piperine as a group,and to lay foundation for developing Fufang Jianghuang microcystis into a safe and effective new drug.
Methods:
①To orally give curcumin microcapsules to the rats;to determine the content of curcumin in plasma and bile by HPLC;to process the data by software DAS2.1;to analyze the pharmacokinetics results of curcumin microcystin in rats.Furthermore,when the ratio ofpiperine and curcumin is 1:9,1:36 or 1:144,to inspect the pharmacokinetics process and evaluate of piperine on the pharmacokinetics of curcumin.
②To cultivate and copy Caco-2 cell model;to apply "two-step portal vein perfusion separation" into normal and hyperlipidemic rat model of liver perfusion in situ,in suspension culture and then to proceed the establishment of primary liver cell model;to Assess cell activity then to carry out experiment of the cytotoxic drug;to calculate the maximum non-toxic concentrations and to determine the maximum dose effect for the experiments.And then to takeβ-GD as the observation indicators to study the reducing difference ofβ-GD activity;Finally,to combine the experimental results of the rats with pharmacokinetic results to determine the effect of best ratio for curcumin and piperine group.
③To divide animals into blank control group,model control group,positive medicine group,Fufang Jianghuang Microcystis high-dose group、Fufang Jianghuang Microcystis low-dose group,high doses of curcumin and curcumin low-dose group;through the tail vein injection of Triton WR-1339 to copy the model of acute hyperlipidemia in rats,and to feed them with high fat emulsion then to copy rats with chronic hyperlipidemia prey model;Then to exam the content of Lipid、fat-metabolizing enzymes、bile acids,and apolipoprotein in animal serum,liver,feces and bile;to evaluate the effect of the Fufang Jianghuang Microcyst;at the same time,to discuss the influence of piperine on the effect of curcumin,then with curcumin alone for comparison.
Results:
①Having identified the methods of extracting curcumin with ethyl acetate and the acid decomposition method in plasma and bile respectively;the results of precision,stability, recovery and processing suggest that the method established in line with the requirements of testing biological samples.
②Bimodal phenomenon of metabolic process has appealed in Microcystis oral formulations of curcumin in rats.When the curcumin is at the level of high,medium and low,the doses of Cmax were 1.16,0.55,2.66 mg / L respectively,the Tmax were 1.5,1.1 and 0.78h respectively,and the AUC y were 3.79,2.60 and 5.92 respectively.This proves that the pharmacokinetics of curcumin is in accordance with the non-linear process,that' s to say,the AUC and Cmax of low-dose,is obviously much higher than that of the high-dose and the middle dose.Compared to the curcumin liposome and suspension,the preparation of the curcumin microcapsules whose peak concentration has been increased to 2.66mg/L when the dose is 58.6mg/kg,which is 5.78 and 5.02 times of liposome and suspension respectivily;the AUC of curcumin microcapsules has been increased to 5.92 mg.h/L,which is 7.6 times and 8.4 times of curcumin liposome and suspension respectively.All the above findings have proved that the curcumin microcapsules have significantly increased the plasma concentration and bioavailability.
③Research on the pharmacokinetics of different ratios of the curcumin and piperine group has been implemented:When piperine for curcumin is 1/9,1/36 or 1/144 and a separate application curcumin,Cmax were 3.45,4.14,2.43,2.23 mg/L;Tmax were 2,3,1.05,0.75 h;AUC were 13.47,16.49,8.7,8.07.It can be seen that after adding piperine, Cmax and AUC have been increased greatly and the Tmax has also been extended, especially when the proportion of curcumin and piperine is 1 to 36,Cmax and AUC has been increased with the greatest scale.Cmax is the 4.14mg/L,which is 9 times and 7.8 times of curcumin liposomes and suspension respectively;AUC is 16.49 mg.h/L,which is 21 times and 23.6 times of curcumin liposome and curcumin suspension respectively.
④Caco-2 cells proliferate at their maximum speed during the period of 3-5 days,so the efficacy studies of the cell has been carried out within this period Experimental study on cytotoxic drugs has showed that when the piperine TC50 is 0.497mg/mL,TC1 is 0.024mg/mL,curcumin TC50 is 3.9247mg/mL,TC1 is 0.098mg/mL,then the curcumin and piperine is 0.098mg/mL and 0.024mg/mL respectively,which is the greatest concentration of drug delivery.
⑤Compared to The control group,in 1h and 3h,when the group of piperine and curcumin is in 1:8～1:33,they could significantly reduce theβ-GD activity of in liver cells; when piperine and curcumin is in 1:8～1:65,they have the function of significantly reducingβ-GD activity in Caco-2 cells.In vivo study,it has been found that when piperine and curcumin group is 1:20,they could greatly decrease the fβ-GD activity in liver and intestinal tissue,while no significant impact has been found on fβ-GD activity in liver and intestinal tissue by using curcumin only.Therefore piperine may play the role of inhibitingβ-GD activity.
⑥Curcumin alone could reduce lipid(TC,TG) content in serum,liver and fecal,which reveals curcumin has a lipid-lowering effect.However,curcumin has no significant impact on lipids(HDL-c and LDL-c) content of serum and liver;nor does it have effect on bile acids,fat-metabolizing enzymes and apolipoprotein of bile and fecal.
⑦Fufang Jianghuang Microcystis(Piperine and curcumin in turmeric 1:20)has the function of significantly lowering serum and liver lipid(TC,TG and LDL-c) and increasing HDL-c content in the role;It could promote bile and faeces in TC,TG and bile acid secretion and excretion of the role;In addition to these,it could also enhance blood apolipoproteins(apoAI,apoB and apoAI / apoB) activity,strengthen the blood and liver lipid metabolism enzymes(LPL,HL,LCAT) activity,as well as enhance the anti-lipid peroxidase(SOD and GSH-PX) activity.
⑧Compared with the separate application of curcumin,Fufang Jianghuang Microcystis has obvious differences in the following aspects:the reduction of blood and liver lipid content;the promotion of bile and feces of TC,TG;bile acid excretion,the enhancement of apolipoprotein,lipid metabolizing enzymes and anti-lipid oxidase activity.
Conclusion:
①A stable method to exam the curcumin in plasma and bile by HPLC has been established.
②The pharmacokinetics of curcumin microcystis in the rat is consistent with the non-linear process.Curcumin in the plasma concentration-time curve is bimodal.It may be caused by enterohepatic circulation,or by the rapid distribution to other organizations, that's to say the second absorption of the blood leads to the emergence of the second peak. AUC and Cmax of low-dose are significantly higher than that of the high-dose and the medium-dose,which could be explained by the fact that the low-dose is mostly near to that of the clinical efficacy dose and animal consumption,so it is more easily absorbed into the blood.
③Compared with the preparations of curcumin liposome and suspension,the curcumin microcapsules has markedly enhanced the plasma concentration and bioavailability.Compared with the separate application of curcumin,curcumin plasma concentration and bioavailability has markedly been improved after adding the piperine, which suggests that piperine,as the glucuronosyltransferase inhibitor in the liver and intestine,may increase the bioavailability of curcumin.This research is expected to provide rational reference for the design of its new agents and clinical rational drug use.
④Through in vitro cells experiments and animal experiments in vivo study and the combination of hyperlipidemia in mice as a model to carry out the ratio of curcumin and piperine screening results with the pharmacokinetic studies,the dissertation has found out that 1:20 is best ratio of the piperine with the curcumin.
⑤Fufang Jianghuang microcapsules has a significant hypolipidemic role in mouse model of hyperlipidemia and chronic predator rat model of hyperlipidemia;compared with the separate application of curcumin,Fufang Jianghuang microcapsules is stronger than curcumin alone in the function of regulating the lipid comprehensively.
⑥Fufang Jianghuang Microcystis regulation of blood lipids may be related with the following points:(1)Inhibition of intestinal exogenous lipid absorption,increase of fecal lipid(cholesterol and bile acid) levels,and promotion of lipid excretion;(2)Enhancement of the blood apolipoprotein(apoAI,apoB and apoAI / apoB) and lipase(LPL,HL,LCAT) activity,the promotion of lipid transformation,acceleration of the blood TC and TG in liver lipid metabolism and transport;(3)Enhancement of the activity of the liver lipid metabolism and speeding up TC,TG metabolism,and increase of the bile secretion and bile TC content;(4)By enhancing the capacity of anti-lipid peroxidation(SOD and GSH-PX), to inhibit lipid peroxidation;(5)By lowering the blood and liver lipid content,to resist the fatty liver lesions.
The study is aimed to provide an experimental basis for the group of curcumin and piperine,and to verify that the compound has a clear effect of regulation of blood lipids, and to suggest that the compound may be a safe and effective new drugs of regulation of blood lipids.The study is aIso expected to provide reference for developing new Chinese medicine for lowering the lipid and to explore a new set of methodology suitable for the development of the new Chinese traditional medicine.
研究目的:
本课题以期寻找姜黄素与胡椒碱最佳组方比例;探讨通过微囊化工艺改进后,姜黄素在动物体内的药代动力学过程,以及加入胡椒碱后对姜黄素药代动力学过程的影响;考察姜黄素和胡椒碱组方-复方姜黄微囊的调脂效应,并与单独应用姜黄素相比,加入胡椒碱后对姜黄素的调脂作用的影响。以期解决一直围绕姜黄素水溶性差、稳定性不好、易分解代谢、药理活性低等问题,最大的发挥姜黄素的调脂效应,为姜黄素和胡椒碱组方提供佐证,并为将复方姜黄微囊开发为安全、有效调脂新药打下基础。
研究方法:
①通过传代培养复制Caco-2细胞模型;采用“门静脉二步灌流分离法”进行正常和高脂血症模型大鼠肝脏原位灌流,然后进行悬浮培养建立原代肝细胞模型。进行细胞活性评定后,开展药物细胞毒性实验,计算最大无毒浓度,由此确定药效实验最大给药剂量。然后以与姜黄素肝肠内代谢密切相关的β-GD为观察指标,观察姜黄素与胡椒碱不同比例降低β-GD活性的差异。通过尾静脉注射Triton WR-1339 250mg/kg复制急性小鼠高脂血症模型,考察姜黄素与胡椒碱不同比例的调脂效应,以期确定姜黄素与胡椒碱组方的最佳比例。
②通过灌胃给予不同剂量的姜黄素微囊制剂,用HPLC测定血浆和胆汁中姜黄素的含量,用DAS2.1软件计算结果,分析姜黄素微囊在大鼠体内的药动学过程。并考察姜黄素与胡椒碱为9:1、36:1和144:1时组方-复方姜黄微囊的大鼠体内药动学过程,以及评价胡椒碱对姜黄素药代动力学过程的影响。
③将动物分为空白对照组、模型对照组、阳性药物组、复方姜黄微囊高剂量组、复方姜黄微囊低剂量组、姜黄素高剂量组和姜黄素低剂量组。通过尾静脉注射TritonWR-1339复制急性小鼠高脂血症模型,和灌服高脂乳剂复制慢性食饵性大鼠高脂血症模型,检测动物血清、肝脏组织、粪便和胆汁中脂质、脂肪代谢酶、胆汁酸、载脂蛋白等成分的含量,对姜黄素和胡椒碱组方的调脂效应进行评价。同时与单独应用姜黄素进行比较,探讨胡椒碱对姜黄素调脂效应的影响。
研究结果:
①Caco-2细胞在3-5天内处于对数增殖期,故选择3-5天时的细胞进行药效研究。药物细胞毒性实验研究结果显示,胡椒碱TC_(50)=1.74mmol/L,TC_1=0.084 mmol/L,姜黄素TC_(50)=10.7mmol/L,TC_1=0.25mmol/L,TC_0=0.266 mmol/L,故姜黄素和胡椒碱分别以0.266mmol/L和0.084 mmol/L为药理实验研究的最大给药浓度。
②与细胞对照组相比,在1h和3h时,姜黄素与胡椒碱组方在8:1-33:1之间均有显著降低肝细胞内β-GD活性的作用;姜黄素与胡椒碱组方在8:1-65:1之间均有显著降低Caco-2细胞内β-GD活性的作用。
③与模型组比较,姜黄素与胡椒碱配比C组、配比D组和配比E组(10.4:1-41.6:1)均明显降低小鼠血清TC含量(P＜0.05-0.01);配比D组和配比E组(20.8:1-41.6:1)也明显降低小鼠血清TG含量(P＜0.01)。单独应用姜黄素有明显降低TC含量的作用(P＜0.05);单独应用胡椒碱没有显著性降低TC和TG水平的作用(P＞0.05)。其中配比E组(41.6:1)对TC和TG的抑制率为最高。通过聚类分析发现配比D组(20.8:1)和配比E组抑制TC和TG含量的百分率属同一类,即抑制效应无显著性差异。故在相同抑制效应情况下,应选择药物剂量小即配比D组作为药效实验的最佳配比剂量。
④确定了分别用乙酸乙酯和酸分解法萃取血浆和胆汁中姜黄素的方法;精密度、稳定性和加样回收率等方面的研究结果提示所建立的方法符合生物样品检测的要求。
⑤姜黄素微囊口服制剂在大鼠体内的代谢过程出现双峰现象。姜黄素高、中、低剂量的Cmax分别为1.16、0.55、2.66 mg/L;Tmax分别为1.5、1.1和0.78h;AUC分别为3.79、2.60和5.92。由此可见,姜黄素的药动学符合非线性过程,低剂量AUC和Cmax明显比高、中剂量高。与姜黄素脂质体和混悬液相比,本室制备的姜黄素微囊制剂低剂量以58.6mg/kg灌胃给药,将姜黄素的峰浓度提高到2.66mg/L,分别是姜黄素混悬液和脂质体的5.78和5.02倍;姜黄素微囊的AUC提高到5.92 mg·h/L,分别为姜黄素混悬液和脂质体的7.6倍和8.4倍,说明姜黄素微囊制剂明显提高了血药浓度和生物利用度。
⑥对姜黄素和胡椒碱不同比例组成的复方进行了药动学研究,胡椒碱为姜黄素1/9、1/36、1/144和单独应用姜黄素时,Cmax分别为3.45、4.14、2.43、2.23 mg/L:Tmax分别为2、3、1.05、0.75h;AUC分别为13.47、16.49、8.7、8.07。由此可见,加入胡椒碱后,Cmax和AUC明显升高,Tmax延长,尤其以姜黄素:胡椒碱=36:1的Cmax和AUC升高最明显。其Cmax为4.14mg/L,分别是姜黄素混悬液和姜黄素脂质体的9倍和7.8倍;AUC为16.49 mg·h/L,分别是姜黄素混悬液和姜黄素脂质体的21倍和23.6倍。
⑦姜黄素单独应用对血清、肝脏和粪便中脂质(TC、TG)含量均有降低作用,揭示姜黄素具有一定的降脂效应;但对血清和肝脏中脂质(HDL-C和LDL-C)含量无显著性影响;对胆汁和粪便中胆汁酸、脂肪代谢酶和载脂蛋白也无显著性影响。
⑧姜黄素与胡椒碱以20:1组成的复方姜黄微囊有明显降低血清、肝脏中脂质(TC、TG和LDL-C)和升高HDL-C含量的作用;还有促进胆汁和粪便中TC、TG和胆汁酸分泌和排泄的作用;增强血液载脂蛋白(apoAI、apoB及apoAI/apoB)活性的作用;增强血液和肝脏脂质代谢酶(LPL、HL、LCAT)的活性;此外,还有增强抗脂质过氧化酶(SOD和GSH-PX)的活性等作用。
⑨与单独应用姜黄素相比,复方姜黄素微囊在降低血液和肝脏中脂质含量;促进胆汁和粪便中TC、TG、胆汁酸排泄:增强载脂蛋白、脂质代谢酶和抗脂质过氧化酶的活性等方面有显著性差异。
研究结论:
①通过离体细胞实验的研究,并结合以高脂血症小鼠为模型开展的姜黄素与胡椒碱配比筛选结果,认为20:1是姜黄素与胡椒碱的最佳配比。
②建立了稳定的血浆和胆汁中姜黄素的HPLC检测方法。姜黄素微囊口服制剂在大鼠体内的药代动力学符合非线性过程。在血浆中的姜黄素药时曲线呈双峰现象,可能存在肝肠循环;也可能是因为姜黄素快速分布到其他组织,再次吸收入血导致第二个峰的出现,具体原因尚需进一步研究证实。低剂量的AUC和Cmax明显比高、中剂量高,可能是因为低剂量最接近临床拟用量和动物药效剂量,所以更易吸收入血。
③与姜黄素脂质体和混悬液相比,本室制备的姜黄素微囊制剂明显提高了血药浓度和生物利用度。与单独应用姜黄素相比,加入胡椒碱后姜黄素的血药浓度和生物利用度明显提高,提示胡椒碱作为肝肠内葡萄糖醛酸苷酶结合抑制剂,可能通过抑制肝肠内姜黄素的葡萄糖醛酸化,提高了姜黄素的生物利用度。通过开展本研究,可望为其新制剂的设计和临床合理用药提供参考。
④复方姜黄微囊对高脂血症小鼠模型和慢性食饵性高脂血症大鼠模型均有显著调脂作用;与单独应用姜黄素相比,复方姜黄素微囊的综合调脂效应明显强于单独应用姜黄素。
⑤复方姜黄微囊调脂作用可能与以下几点有关:(1)抑制肠道外源性脂质吸收,增加粪便中脂质(胆固醇和胆汁酸)含量,促进脂质排泄;(2)增强血液载脂蛋白(apoAI、apoB及apoAI/apoB)和脂肪酶(LPL、HL、LCAT)活性,促进血脂转化,加速血液TC和TG的代谢及脂质肝脏转运;(3)增强肝脏脂质代谢酶活性,加速肝脏对TC、TG代谢,增加胆汁分泌及胆汁中TC含量;(4)通过增强抗脂质过氧化能力(SOD和GSH-PX),抑制脂质过氧化;(5)通过降低血液与肝脏脂质含量,抑制肝脏脂肪样病变。
通过本课题的研究,为姜黄素和胡椒碱组方提供了实验依据,并验证了复方姜黄微囊有明确的调脂效应,提示复方姜黄微囊可能是一种有发展前景的有效调脂新药,以期为降脂中药新药的研发提供参考,探索出一套适合于中药新药研究的新思路和方法。
Hyperlipidemia,a disease of disorder of lipid metabolism in human,leads to the fact that plasma lipid concentrations exceed the normal range.Therefore,It is the major factor that causes atherosclerosis,coronary heart disease and high blood pressure.However,in recent years,the incidence of hyperlipidemia has been rising increasingly,and most of the lipid lowering drugs have only short-term efficacy,while Long-term use will result in toxicity.Therefore,to find safe and effective lipid lowering drugs from the traditional Chinese and natural medicine is the present trend for the treatment of the Hyperlipidemia. On one hand,the traditional Chinese medical diagnosis and treatment is characterized by its dialectic,which means,more specifically,an individual treatment basing on the patient,the time of the illness as well as the place where the treatment is implemented.On the other hand,the traditional Chinese medicine could integrate all its regulatory function through multi-links,multi-levels,multi-targets,which is in accordance with the diversity in human body.Curcumin has lots of pharmacological functions,such as curing hypolipidemic, anti-mutagenic,anti-oxidation,scavenging free radicals,which renders it to become more promising than other drugs in the treatment of hyperlipidemia.However,curcumin itself has a number of problems,such as high-fat-soluble,small water solubility,poor stability, easy decomposition and transformation in the liver and intestine,resulting in low serum concentration,poor bioavailability and large doses,which greatly limit its clinical use and the development of new drugs.To solve these problems,the dissertation combines curcumin with piperine,the glucuronosyltransferase inhibitors of liver and intestinal.By inhibiting the glucuronic acid of curcumin,the metabolism of curcumin will be reduced; and the use of micro - capsule technology will increase its stability and water-soluble, promote its absorption,reduce the frequency of use,and maintain a lasting effect;all the above will enhance its bioavailability.The main research topics of the dissertation are as follows:
Objective:
The dissertation firstly tries to explore the changes of the pharmacokinetics process of curcumin in rats after the technical improvement through the microcapsules as well as the effect after adding the piperine.Basing on the above experiment,the author manages to find the best set of square ratio of curcumin with piperine;Then,the author also studies the blood lipid regulating effects of Fufang Jianghuang microcystis,a Chinese medicine whose main ingredient is curcumin and piperine and compares the blood lipid regulating effects after the adding of piperine.Finally,The dissertation tries to solve those disadvantages of Curcumin,such an small water solubility,poor stability,easy decomposition and transformation and the low pharmacological activity,so as to realize the full play of the lipid effects of curcumin,to provide support for curcumin and piperine as a group,and to lay foundation for developing Fufang Jianghuang microcystis into a safe and effective new drug.
Methods:
①To orally give curcumin microcapsules to the rats;to determine the content of curcumin in plasma and bile by HPLC;to process the data by software DAS2.1;to analyze the pharmacokinetics results of curcumin microcystin in rats.Furthermore,when the ratio ofpiperine and curcumin is 1:9,1:36 or 1:144,to inspect the pharmacokinetics process and evaluate of piperine on the pharmacokinetics of curcumin.
②To cultivate and copy Caco-2 cell model;to apply "two-step portal vein perfusion separation" into normal and hyperlipidemic rat model of liver perfusion in situ,in suspension culture and then to proceed the establishment of primary liver cell model;to Assess cell activity then to carry out experiment of the cytotoxic drug;to calculate the maximum non-toxic concentrations and to determine the maximum dose effect for the experiments.And then to takeβ-GD as the observation indicators to study the reducing difference ofβ-GD activity;Finally,to combine the experimental results of the rats with pharmacokinetic results to determine the effect of best ratio for curcumin and piperine group.
③To divide animals into blank control group,model control group,positive medicine group,Fufang Jianghuang Microcystis high-dose group、Fufang Jianghuang Microcystis low-dose group,high doses of curcumin and curcumin low-dose group;through the tail vein injection of Triton WR-1339 to copy the model of acute hyperlipidemia in rats,and to feed them with high fat emulsion then to copy rats with chronic hyperlipidemia prey model;Then to exam the content of Lipid、fat-metabolizing enzymes、bile acids,and apolipoprotein in animal serum,liver,feces and bile;to evaluate the effect of the Fufang Jianghuang Microcyst;at the same time,to discuss the influence of piperine on the effect of curcumin,then with curcumin alone for comparison.
Results:
①Having identified the methods of extracting curcumin with ethyl acetate and the acid decomposition method in plasma and bile respectively;the results of precision,stability, recovery and processing suggest that the method established in line with the requirements of testing biological samples.
②Bimodal phenomenon of metabolic process has appealed in Microcystis oral formulations of curcumin in rats.When the curcumin is at the level of high,medium and low,the doses of Cmax were 1.16,0.55,2.66 mg / L respectively,the Tmax were 1.5,1.1 and 0.78h respectively,and the AUC y were 3.79,2.60 and 5.92 respectively.This proves that the pharmacokinetics of curcumin is in accordance with the non-linear process,that' s to say,the AUC and Cmax of low-dose,is obviously much higher than that of the high-dose and the middle dose.Compared to the curcumin liposome and suspension,the preparation of the curcumin microcapsules whose peak concentration has been increased to 2.66mg/L when the dose is 58.6mg/kg,which is 5.78 and 5.02 times of liposome and suspension respectivily;the AUC of curcumin microcapsules has been increased to 5.92 mg.h/L,which is 7.6 times and 8.4 times of curcumin liposome and suspension respectively.All the above findings have proved that the curcumin microcapsules have significantly increased the plasma concentration and bioavailability.
③Research on the pharmacokinetics of different ratios of the curcumin and piperine group has been implemented:When piperine for curcumin is 1/9,1/36 or 1/144 and a separate application curcumin,Cmax were 3.45,4.14,2.43,2.23 mg/L;Tmax were 2,3,1.05,0.75 h;AUC were 13.47,16.49,8.7,8.07.It can be seen that after adding piperine, Cmax and AUC have been increased greatly and the Tmax has also been extended, especially when the proportion of curcumin and piperine is 1 to 36,Cmax and AUC has been increased with the greatest scale.Cmax is the 4.14mg/L,which is 9 times and 7.8 times of curcumin liposomes and suspension respectively;AUC is 16.49 mg.h/L,which is 21 times and 23.6 times of curcumin liposome and curcumin suspension respectively.
④Caco-2 cells proliferate at their maximum speed during the period of 3-5 days,so the efficacy studies of the cell has been carried out within this period Experimental study on cytotoxic drugs has showed that when the piperine TC50 is 0.497mg/mL,TC1 is 0.024mg/mL,curcumin TC50 is 3.9247mg/mL,TC1 is 0.098mg/mL,then the curcumin and piperine is 0.098mg/mL and 0.024mg/mL respectively,which is the greatest concentration of drug delivery.
⑤Compared to The control group,in 1h and 3h,when the group of piperine and curcumin is in 1:8～1:33,they could significantly reduce theβ-GD activity of in liver cells; when piperine and curcumin is in 1:8～1:65,they have the function of significantly reducingβ-GD activity in Caco-2 cells.In vivo study,it has been found that when piperine and curcumin group is 1:20,they could greatly decrease the fβ-GD activity in liver and intestinal tissue,while no significant impact has been found on fβ-GD activity in liver and intestinal tissue by using curcumin only.Therefore piperine may play the role of inhibitingβ-GD activity.
⑥Curcumin alone could reduce lipid(TC,TG) content in serum,liver and fecal,which reveals curcumin has a lipid-lowering effect.However,curcumin has no significant impact on lipids(HDL-c and LDL-c) content of serum and liver;nor does it have effect on bile acids,fat-metabolizing enzymes and apolipoprotein of bile and fecal.
⑦Fufang Jianghuang Microcystis(Piperine and curcumin in turmeric 1:20)has the function of significantly lowering serum and liver lipid(TC,TG and LDL-c) and increasing HDL-c content in the role;It could promote bile and faeces in TC,TG and bile acid secretion and excretion of the role;In addition to these,it could also enhance blood apolipoproteins(apoAI,apoB and apoAI / apoB) activity,strengthen the blood and liver lipid metabolism enzymes(LPL,HL,LCAT) activity,as well as enhance the anti-lipid peroxidase(SOD and GSH-PX) activity.
⑧Compared with the separate application of curcumin,Fufang Jianghuang Microcystis has obvious differences in the following aspects:the reduction of blood and liver lipid content;the promotion of bile and feces of TC,TG;bile acid excretion,the enhancement of apolipoprotein,lipid metabolizing enzymes and anti-lipid oxidase activity.
Conclusion:
①A stable method to exam the curcumin in plasma and bile by HPLC has been established.
②The pharmacokinetics of curcumin microcystis in the rat is consistent with the non-linear process.Curcumin in the plasma concentration-time curve is bimodal.It may be caused by enterohepatic circulation,or by the rapid distribution to other organizations, that's to say the second absorption of the blood leads to the emergence of the second peak. AUC and Cmax of low-dose are significantly higher than that of the high-dose and the medium-dose,which could be explained by the fact that the low-dose is mostly near to that of the clinical efficacy dose and animal consumption,so it is more easily absorbed into the blood.
③Compared with the preparations of curcumin liposome and suspension,the curcumin microcapsules has markedly enhanced the plasma concentration and bioavailability.Compared with the separate application of curcumin,curcumin plasma concentration and bioavailability has markedly been improved after adding the piperine, which suggests that piperine,as the glucuronosyltransferase inhibitor in the liver and intestine,may increase the bioavailability of curcumin.This research is expected to provide rational reference for the design of its new agents and clinical rational drug use.
④Through in vitro cells experiments and animal experiments in vivo study and the combination of hyperlipidemia in mice as a model to carry out the ratio of curcumin and piperine screening results with the pharmacokinetic studies,the dissertation has found out that 1:20 is best ratio of the piperine with the curcumin.
⑤Fufang Jianghuang microcapsules has a significant hypolipidemic role in mouse model of hyperlipidemia and chronic predator rat model of hyperlipidemia;compared with the separate application of curcumin,Fufang Jianghuang microcapsules is stronger than curcumin alone in the function of regulating the lipid comprehensively.
⑥Fufang Jianghuang Microcystis regulation of blood lipids may be related with the following points:(1)Inhibition of intestinal exogenous lipid absorption,increase of fecal lipid(cholesterol and bile acid) levels,and promotion of lipid excretion;(2)Enhancement of the blood apolipoprotein(apoAI,apoB and apoAI / apoB) and lipase(LPL,HL,LCAT) activity,the promotion of lipid transformation,acceleration of the blood TC and TG in liver lipid metabolism and transport;(3)Enhancement of the activity of the liver lipid metabolism and speeding up TC,TG metabolism,and increase of the bile secretion and bile TC content;(4)By enhancing the capacity of anti-lipid peroxidation(SOD and GSH-PX), to inhibit lipid peroxidation;(5)By lowering the blood and liver lipid content,to resist the fatty liver lesions.
The study is aimed to provide an experimental basis for the group of curcumin and piperine,and to verify that the compound has a clear effect of regulation of blood lipids, and to suggest that the compound may be a safe and effective new drugs of regulation of blood lipids.The study is aIso expected to provide reference for developing new Chinese medicine for lowering the lipid and to explore a new set of methodology suitable for the development of the new Chinese traditional medicine.
引文
[1]陈灏珠.我国人群血脂水平现状和高脂血症的治疗.中西医结合学报[J],2004,2(2):81-82.
[2]宗蕾,陆伦根.调血脂药与肝脏安全性.中国肝脏学,2008;13(6):510-512.
[3]张占柱.从痰、瘀、虚论治高脂血症[J].河南中医药学刊,1999;14(6):45-51.
[4]杨智敏.高脂血症的中医药治疗研究初探[J].现代医药卫生,2005;21(23):3241-3242.
[5]于克娇.中医对高脂血症的认识和治疗现状[J].中国航天工业医药,2000;(4):79-80.
[6]周美芳.从痰瘀论治高脂血症88例临床观察[J].贵阳中医学院学报,2005;27(1):43.
[7]熊原.加味半夏白术天麻汤治疗高血压并高脂血症的临床研究[J].河北中医,2005;27(10):751-752.
[8]陈苏宁,杨积武,张放,等.血府逐瘀汤加减治疗高脂血症100例[J].辽宁中医杂志,2001:28(6):364-365.
[9]陆新.加味天麻钩藤饮治疗高脂血症的临床观察.湖北中医杂志,2004;26(4):13-14.
[10]吕正有.中药降脂汤治疗高脂血症临床疗效观察[J].辽宁中医药大学学报,2008;4(10):98-99.
[11]王忠壮译.牛膝抗炎和抗高胆固醇血症成份的研究.国外医学植物药分册,1994;9(3):122.
[12]张馨木,曲绍春,睢大员,等.人参Rb组皂苷对高脂血症大鼠血脂代谢的影响及其抗氧化作用.中国中药杂志,2004;29(11):1085-1088.
[13]宋士军,李芳芳,尹智玮,等.何首乌对实验性高脂血症作用的研究.河北中医药学报,2003;18(4):27-28.
[14]高莹,肖颖.山楂及山楂黄酮提取物调节大鼠血脂的效果研究.中国食品卫生杂志,2002;14(3):14-16.
[15]董加喜,王梅娟.富含川芎嗪脂质体对实验性动脉粥样硬化家兔的降脂和抗氧化作用.中国中医药科技,1997;4(6):F003.
[16]刘宏雁.刺五加总皂甙对实验性高脂血症大鼠血脂的影响.白求恩医科大学学报,1995:21(4):34.
[17]李林,邢善国,周金黄.绞股蓝总皂甙对离体大鼠肝脏脂质过氧化及膜流动性损 伤的保护作用.中国药理学报,1991;7(5):342.
[18]裴莲花,吴学,金光洙.虎杖化学成分及药理作用研究现状.延边大学医学学报,2006;29(2):147-149.
[19]何菊英,刘松青.决明子的药理作用及其临床应用.药学实践杂志,2001;19(2):111-113.
[20]周利玲,吴和平,李树平,等.大黄素对鹌鹑脂质代谢的影响研究。怀化医专学报,2005;4(2):12-15.
[21]王金红,高尔.乳化葛根素对高脂血症家兔模型调血脂和抗氧化作用.潍坊医学院学报,2001;23(1):6.
[22]罗琼,李瑾玮,张声华.枸杞及其多糖对家兔血脂的影响.食品科学,1997;18(4):5.
[23]孙涛,王厚龙,孙凤发.灵芝的药用价值与栽培技术.人参研究,2007;(2):23-24
[24]陈凯,陈凤兰.中西医结合治疗高脂血症62例疗效观察[J].新中医,2006;38(1):58.
[25]赵峥,范中有.中西医结合治疗高脂血症127例疗效观察[J].四川中医,2005;23(10):56.
[26]冯蓉.中西医结合治疗高脂血症56例临床观察[J].四川中医,2005;23(1):56.
[27]杨云,张晶,陈玉婷.天然药物化学成分提取分离手册(修订版).中国中医药出版社,2003:584
[28]Tonnesen HH,Masson M,Loftsson T.Studies of curcumin and curcuminoids ⅩⅩⅦ.Cyclodextrin complexation:Solubility,chemical and photochemical stability[J].Int J Pharm2002;(244):127.
[29]沃兴德,崔小强,唐利华.姜黄素对食饵性高脂血症大鼠血浆脂蛋白代谢相关酶活性的影响[J].中国动脉硬化杂志,2003;7(4):339-341.
[30]Fan Chunlei,Qian Ying,Wo Xingde,et al.Effect of Curcumin on the Gene Expression of Low Density Lipoprotein Receptors[J].Chin J Integr Med,2005;11(3):201-204.
[31]窦晓兵,范春雷,洪行球,等.姜黄素对人淋巴细胞人低密度脂蛋白受体表达影响的研究[J].中国药学杂志,2005;40(13):980-982.
[32]Babu PS et al.Hypolipidemic action of curcumin,the active principle of turmeric (CurcuminLonga) in streptozotoc ininduced diabetic rats[J].Mol-Cell-Biochem,1997;166(1-2):169-175.
[33]沃兴德,洪行球,高承贤,等.姜黄素长期毒性实验.浙江中医学院学报,2000;24(1):61-64.
[34]王舒然,陈炳卿,孙长颢.姜黄素对大鼠调血脂及抗氧化作用的研究[J].卫生研究,2000;29(4):241
[35]沃兴德.姜黄素对低密度脂蛋白和脂蛋白(a)代谢的影响[J].中国动脉硬化杂志,1999;7(4):33.
[36]潘赞红,李薇,金鑫.姜黄素对高脂血症动物的实验研究[J].天津中医,1999;16(5):35.
[37]孙秀才,冯建章,斐晓阳,等.姜黄素对食高脂饲料家兔血管内皮功能的保护作用[J].岭南医学杂志,2004;10(1):60-63.
[38]张丽,梁中琴,顾振纶.姜黄素对内皮细胞的保护作用及机制研究[J]中国药理通讯,2003:20(2):56.
[39]Amaswami G,Chai H,Yao Q,et al.Curumin block hompcusteine-induced endothelial dysfunction in porcine coronaary arteries[J].J Vase surg,2004;40(6):1216-1222.
[40]王政,惠伯棣,裴凌鹏,等.大鼠体内类姜黄素的组成变化.食品科学,2007;28(9):542-545.
[41]王旗,王夔.姜黄素的代谢研究[J].中国药理学通报,2003;19(10):1097-1102.
[42]Holder GM,Plummer JL,Ryan AJ.The metabolism and excretion of curcumin(1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat.Xenobiotica,1978;8(12):761-768.
[43]Ravindranath V,Chandrasekhara N.Absorption and tissue distribution of curcumin in rats.Toxicology,1980;16(3):259-265.
[44]许汉林,孙芸,邵继征,等.姜黄素脂质体在大鼠体内药代动力学研究[J].湖北中医学院学报,2007;(1):42-43.
[45]韦晓瑜,陈世忠.姜黄素注射液在大鼠体内的药代动力学[J].北京大学学报(医学版),2003;35(3):230.
[46]Pan MH,Huang TM,Lin JK,et al.Biotransformation of curcumin through reduction and glucuronidation in mice[J].Drug Metab Dispos,1999;27(4):486-491.
[47]温彩霞,许建华,黄秀旺.姜黄素在小鼠体内各脏器的药代动力学研究[J].中药药理与临床,2007;(4):25-26.
[48]Pan MH,Huang TM,Lin JK.Biotransformation of curcumin through reduction and glucuroni dation in mice.Drag Metabolitism & Disposition,1999;27(4):486-494.
[49]Cheng AL,Hsu CH,Lin JK.Phase I clinical trial of curcumin,a chemopreventive agent,in patients with high-ris kor pre-malignant lesions.Anticancer Res,2001;21:2895-2900.
[50]Ruffin MT,Normolle DP,Heath DD.Dose escalation of curcumin in healthy adults,CancerEpidem Biomar Prevent,2003;12:1324-1340.
[51]Sharma RA,MC Lell.,Hill KA.Pharmacodynamic and Pharmacokinetic study of oral curcuma extract in patients with colorectal cancer.Clin Cancer Res,2001;7:1894-1900.
[52]Ireson CR,Jones D,Orr S,et al.Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine[J].Cancer Epidemiol Biomarkers Prev,2002;11(1):105-111.
[53]Shoba G,Joy D,Joseph T,et al.Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers[J].Planta Medica,1998;64:353-356.
[54]Tonnesen HH,Masson M,Loftsson T.Studies of curcumin and curcuminoids ⅩⅩⅦ.Cyclodextrin complexation:Solubility,chemical and photochemical stability[J].Int J Pharm,2002;(244):127-132.
[55]Lee SA,Hong SS,Han XH,et al.Piperine from the fruits of piperlongum with inhibitory effect on monoamine oxidase and antide-pressant-like activity[J].Chem Pharm Bull(Tokyo),2005;53(7):832-836.
[56]Bajad S,Bedi KL,Singla AK,et al.Antidiarrhoeal activity of piperine in mice[J].Planta Med,2001;67(3):284-288.
[57]Szolcsanyi J,Bartho L.Capsaicin-sensitive afferents and their role in gastroprotection:an update[J].J Physiol Paris,2001;95(1-6):181-186.
[58]Morikawa T,Matsuda H,Yamaguchi I,et al.New amides and gas-tro protective constituents from the fruit of piperchaba[J].Planta Med,2004;70(2):152-157.
[59]于腾飞,刘屏,王东晓,等.胡椒碱对过氧化氢损伤大鼠心肌线粒体的保护作用及机制研究.解放军药学学报,2008;24(1):7-9.
[60]白永忠.胡椒碱对兔实验性动脉粥样硬化的预防作用.中国民族医药杂志,2002;8(3):35-36.
[61]包兰兰,金桩.胡椒碱降血脂作用的实验研究.中国民族医药杂志,2004;(1):22-23
[62]Vijayakumar RS,Surya D,Nalini N.Antioxidant efficacy of black pepper(Piper nigrum L.)and piperine in rats with high fat diet induced oxidative stress[J].Redox Rep,2004;9(2):105-109.
[63]Mittal R,Gupta RL.In vitro antioxidant activity of piperine[J].Methods Find Exp Clin Pharmacol,2000;22(5):271-276.
[64]李月廷,王海梅,吴恩,等.胡椒酸甲酯对大鼠血清胆固醇的调整作用及机理.中草药,1993;24(1):27-29.
[65]Dogra RK,Khanna S,Shanker R.Immunotoxicological effects of piperine in mice[J].Toxicology,2004;196(3):229-233.
[66]海英,那生桑,双福,等.荜茇胡椒碱致畸试验研究.世界科学技术-中医药现代化,2008;10(1):133-137
[67]R M otterlini,R Foresti,R Bassi,et al.Curcumin,an antioxidant and anti-inflammatory agent,induces heme oxygenase-land protects endothelial cells against oxidative stress[J].Free Radic BiolMed,2000;28(8):1303-1307.
[68]Shoba G,Joy D,Joseph T,et al.Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.Planta Medica,1998;64:353-358.
[69]Sujata MK,Priyadarsini KI,Palit DK,et al.Effect of Solvent on the Excited-state photophysical properties of curcumin[J].PhotochemPhotobiol,2000;72(5):625-631.
[70]Barik KA,Priyadarsini,Hari Mohan.Photophysical studies on binding of curcumin to bovine serum albumin[J].PhotochemPhotobiol,2003;77(6):597-602.
[71]Erika Pfeiffer,Simone Hohle,Aniko MS,et al.Studies on the stability of turmeric constituents[J].J of Food Engineering,2003;56:257-263.
[72]Bhardwaj RK,Glaeser H,Becquemont L,et al.Piperine,a major constituent of black pepper,inhibits human P-glycoprotein and CYP3A4[J].J Pharmacol Exp Ther,2002;302(2):645-649.
[73]Gupta SK,Bansal P,Bhardwaj RK.Comparativeanti-nociceptive,anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination[J].Pharmacol Res,2000;41(6):657-661.
[74]Hiwale AR,Dhuley JN,Naik SR.Effect of co-administration of piperine on pharmacokinetics of beta-lactam antibiotics in rats[J].Indian J Exp Biol,2002;40(3):277-281.
[75]Velpandian T,Jasuja R,Bhardwaj RK,et al.Piperine in food:inter-ference in the pharmacokinetics of phenytoin[J].Eur J Drug Metab Pharmacokinet,2001;26(4):241-246.
[76]Khajuria A,Thusu N,Zutshi U.Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics:influence on brush border membrane fluidity,ultra-structure and enzyme kinetics[J].Phyto Medicine,2002;9(3):224-230.
[1]王春彬,高大中.姜黄素的研究进展以及在心血管疾病中的应用.心血管病学进展,2005;26(6):614-616.
[2]Pan MH,Huang TM,Lin JK.Biotransformation of curcumin through reduction and glucuronidation in mice.Drug Metabolitism & Disposition,1999;27(4):486-494.
[3]Ireson C.R.,Jones D.J.L,Orr S.Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine.Cancer Epidem Biomar Prevent,2002;(11):97-104.
[4]曾苏.加强药学领域中药物代谢的研究.浙江大学学报(医学版),2008;37(2):109-113.
[5]刘磊,邓敏,高人焘,等.几种药物对HepG2细胞MRP2表达的影响[J].实用肝脏病杂志,2006;9(6):333-336.
[6]关溯.Caco-2细胞模型一药物吸收研究的有效工具[J].中国药理学通报,2004;20(6):609-613.
[7]刘昌孝.中药药代动力学研究的难点和热点.药学学报,2005;40(5):398.
[8]高坤,孙进,何仲贵.Caco-2细胞模型在口服药物吸收研究中的应用.沈阳药科大学学报,2005;22(62):479-484.
[9]Cheng Y.姜黄素降低结肠癌Caco-2细胞中酸性神经鞘磷酯酶活性.国外医药·植物药分册,2008;23(4):181-182.
[10]Nishimura N.Effects of Chinese herbal medicines on intestinal drug absorption.YakugakuZusshi,2005;125(4):363-369.
[11]WANG Y,CAO J,ZENG S.Involvement of P.glycoprotein in regulating cellular levels of Ginkgo flavonols:quercetin,kaempferol,and isorhamnetinfJ].J P Pharmaeof,2005;57(6):751-758.
[12]GUAN S,BI H C,CHEN X,et al.Transport mechanism of totanshinone across Caco-2 monolayer model.ClinPharmax'ol(中国临床药理学杂志),2005:21(4):268-271.
[13]Zheng Y,Yang XW,J Chin Integr Med.Zhong Xi Yi Jie He Xue Bao,2008:6(7):704-710
[14]Kato M,Chiba K,Horikawa M,et al.The quantilative prediction of in vivo enzyme induction caused by drug exposure from in vitro information on human hepatocytes [J].Drug Metab Pharmacokinet,2005;(20):236.
[15]张文军,娄建石,董伟林,等.布洛芬在损伤后原代培养大鼠肝细胞中代谢的研究.中国药学杂志,2008;43(6):472-474
[16]蔡燕,戚新明,宫丽崑,等.汉防已甲素诱导大鼠原代肝细胞线粒体途径的凋亡:依赖于caspase和由Endonuclease G(Endo G)介导的不依赖于caspase的凋亡途径.毒理学杂志,2005:19(3):219-220
[17]李素婷,姜凌雪,周晓慧,等.柴胡皂苷d对乙醇损伤原代培养大鼠肝细胞的保护作用及其机制研究.时珍国医国药,2008;19(11):2752-2753
[18]谭洪玲,杨明会,王宇光,等.大鼠原代肝细胞培养方法的建立.中国应用生理学杂志,2006:22(4):509-512
[19]Shibata Y.Takahashi H.Ishil Y.A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocyts suspended in serum.Drug metab and dispos,2000;28:15-18.
[20]Annaert P.Brower KR.Assessment of drug in]eractions in hepatobiliary transport using rhodaminel 23 in sandwich cultured rat hepatocytes[J].Drug metab and dispos,2005;33:388.
[21]Hariparsad N,Sane RS,Strom SC,et al.In vitro methods in human drug biotransformation research:implications for cancer chemotherapy.Toxicology in Vitro,2006;20:135.
[22]徐哲,白雪帆.腾光菊,等.微载体黏附培养SD大鼠肝细胞的生物学特性.第四军医大学学报,2004;25(5):135.
[23]Seglen PO.Preparation of rat liver cells I,effect of Ca~(2+) on enzymatic dispersion of isolated perfused liver[J].Exp Cell Res,1972;74:450-455.
[24]贾珍容,邱银生,王大菊,等.比较两种消化酶对分离大鼠肝细胞的影响.中国药师,2006;9(7):590-593
[25]庄鹏,李志莹,范紫香,等.改良原代大鼠肝细胞的体外分离培养和功能研究.热带医学杂志,2008;8(10):1024-1027.
[1]许汉林,孙芸,邵继征,等.姜黄素脂质体在大鼠体内药代动力学研究[J].湖北中医学院学报,2007;9(1):42-43.
[2]刘安昌,娄红祥,赵丽霞.姜黄素药理活性及体内代谢[M].国外医学:植物药分册,2004;19(1):1-5.
[3]王旗,王夔.姜黄素的代谢研究[J].中国药理学通报,2003;19(10):1097-1012.
[4]张继芬,侯世祥,刘惠莲,等.小鼠血浆中姜黄素的含量测定及药动学研究[J].中国药学杂志,2007;42(4):288-290.
[5]刘安昌,娄红祥,赵丽霞.姜黄素在大鼠体内的代谢研究[J].上海中医药杂志,2008;42(8):74-77.
[6]陆兔林,毛春芹,卞慧敏,等.莪术中姜黄素在大鼠体内的药动学研究[J].中草药,2005;36(8):1157-1158.
[7]韩刚,张义春,刘士勇,等.姜黄中姜黄素含量测定方法的比较[J].西北药学杂志,2005;20(1):15-16.
[8]刘晓亮,张宇,孙蕴哲,等.水飞蓟宾脂质微球的制备及在大鼠体内的药物动力学考察.沈阳药科大学学报,2008;25(6):423-428.
[9]许汉林,孙芸,邵继征,等.姜黄素脂质体在大鼠体内药代动力学研究[J].湖北中医学院学报,2007;(1):42-43.
[10]Shoba G,Joy D,Joseph T,et al.Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers[J].Planta Medica,1998;64:353-356.
[1]高敏,淤泽溥,赵远,等.用Triton WR-1339复制小鼠高脂血症动物模型的研究.云南中医中药杂志,2008,29(6):46-47.
[2]刘明,董超仁,苏静怡.一种简易大鼠高脂血症模型[J].中国药理学通报,1989;5(2):119-120.
[3]徐叔云,卞如濂,陈修,等.药理实验方法学.人民卫生出版社,2003;第三版:1319.
[4]王倩,汪海.新化合物哌芳安他对兔和鹌鹑高脂血症性脂肪肝的影响.中国药理学通报,2003;19(12):1349-1353.
[5]方叶青,杨天伦,陈小彬.血脂比值和单项血脂与冠脉狭窄程度的相关分析.湘南学院学报(医学版),2006;8:7-8.
[6]Cleeman JI.Executive summary of the third report of the national cholesterol education program(NCEP)expert panel on detection,evaluation,and treatment of high blood cholesterol in adults(adults treatment panelⅢ)[J].JAMA,2001;285:2486-2497.
[7]蒋宪成,庄庆祺,梅美珍.卵磷脂胆固醇酰基转移酶活性的简易测定法.上海第一医学院学报,1985,12(2):259.
[8]王伯远,李坟松,黄高异,等主编.组织的取材和固定方法.病理学技术,人民卫生出版社,2000:74.
[9]王伯远,李坟松,黄高异,等主编.染色基石原理、生物染料和苏木精-伊红染色方法.病理学技术,人民卫生出版社,2000:30-132.
[1]王政,惠伯棣,裴凌鹏,等.大鼠体内类姜黄素的组成变化.食品科学,2007;28(9):542-545.
[2]Ireson C R,JonesD JL,OrrS,et al.Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine[J].Cancer Epidemiol Biomarkers Prey,2002;11(1):105-111.
[3]王春彬 综述 高大中.姜黄素的研究进展以及在心血管疾病中的应用.心血管病学进展,2005;26(6):614-616.
[4]Pan MH,Huang TM,Lin JK.Biotransformation of curcumin through reduction and glucuronidation in mice.Drug Metabolitism & Disposition,1999;27(4):486-494.
[5]ShobaG,Joy D,Joseph T,et al.Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers[J].Planta Medica,1998;64:353-356.
[6]杨海涛,王广基,Caco-2单层细胞模型及其在药学中的应用[J].药学学报,2000;35(10):797-800.
[7]Jumarie C,Malo C.Caco-2 cells cultured in serum free medium as a model for the study of enterocytic differentiation in vitro[J].J Ce Ⅱ Physiol,1991;149(1):24-33.
[8]Artursson P,Karlsson J.Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial(Caco-2)cells[J].Biochem Biophys Res Commun,1991;175(3):880-885.
[9]Westphal K,Weinbrenner A,Zschiesche M,et al.Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings:A new typeof drug /drug interaction[J].Clin Pharmacol Ther,2000;68(4):345-355.
[10]Hiroshi S,Yuichi S.Role of metabolic enzymes and ef-flux transporters in the absorption of drugs from the small intestine[J].Eur J Pharm Sci,2000;12(1):3-12.
[11]Phung-Ba V,Wamery A,Scherman D,et al.Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells[J].Eur J Pharmacol,1995;288(2):187-192.
[12]Hunter J,Jepson M A,Tsuruo T,et al.Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells[J].J Biol Chem,1993;268(20):14991-14997.
[13]薛俊峰,李桦,阮金秀,等.氮烯乙茶在成年大鼠肝细胞中的生物转化[J].药学学报,1999;34(10):739.
[14]贾珍容,邱银生,王大菊,等.比较两种消化酶对分离大鼠肝细胞的影响.中国药师,2006:9(7):590-593.
[15]包晓华,巴根那,白明纲,等.HPLC法测定协日嘎四味片中姜黄素类成分的含量. 中国民族医药杂志,2009;1:42-44.
[16]崔红彬,孟建升,蒋俊春,等.HPLC法测定姜黄片中姜黄素的含量.中国药师,2008;11(9):1071-1072.
[17]Ravindranath V,Chandrasekhara N.Absorption and tissue distribution of curcumin in rats.Toxicology,1980;16(3):259-265.
[18]许汉林,孙芸,邵继征,等.姜黄素脂质体在大鼠体内药代动力学研究[J].湖北中医学院学报,2007;9(1):42-43.
[19]Kris-Etherton PM and D iteschy J.Design criteria for studies examing individual fatty acid effects on cardiovascular disease risk factors:human and animal studies.Am J Clin Nutr,1997;65(1):1594-1598.
[20]王威,江海涛,李玉红,等.小鼠、大鼠高甘油三酯血症、脂肪肝模型的比较.天津中医药,2006;47(7):192-194.
[21]刘明,董超仁,苏静怡.一种简易大鼠高脂血症模型[J].中国药理学通报,1989;5(2):119-120.
[22]何峰,邵海琳,林展增,等.血脂及血清载脂蛋白A I、B测定对冠心病诊断的意义.河北北方学院学报·医学版,2005;22(6):34-35.
[23]郭虹,陈在嘉,徐义枢.血清脂质与脂质过氧化关系的临床研究.中国循环杂志,1999;6(5):373-375.
[1]沃兴德,崔小强,唐利华.姜黄素对食饵性高脂血症大鼠血浆脂蛋白代谢相关酶活性的影响[J].中国动脉硬化杂志,2003;7(4):339-341.
[2]Fan Chunlei,Qian Ying,Wo Xingde,et al.Effect of Curcumin on the Gene Expression of Low Density Lipoprotein Receptors[J].Chin J Integr Med,2005;11(3):201-204.
[3]窦晓兵,范春雷,洪行球,等.姜黄素对人淋巴细胞人低密度脂蛋白受体表达影响的研究[J].中国药学杂志,2005:40(13):980-982.
[4]Babu PS.Hypolipidemic action of curcumin,the active principle of turmeric(Curcumin Longa) in streptozotoc ininduced diabetic rats[J].Mol-Cell-Biochem,1997;166(1-2):169-175.
[5]沃兴德,洪行球,魏佳萍,等.姜黄醇提取物对高脂血症患者脂代谢及肝肾功能的影响[J].浙江中医学院学报,1999;23(1):2022.
[6]王舒然,陈炳卿,孙长颢.姜黄素对大鼠调血脂及抗氧化作用的研究[J].卫生研究,2000:29(4):241.
[7]沃兴德.姜黄素对低密度脂蛋白和脂蛋白(a)代谢的影响[J].中国动脉硬化杂志,1999;7(4):33.
[8]潘赞红,李薇,金鑫.姜黄素对高脂血症动物的实验研究[J].天津中医,1999;16(5):35.
[9]孙秀才,冯建章,斐晓阳,等.姜黄素对食高脂饲料家兔血管内皮功能的保护作用[J].岭南医学杂志,2004;10(1):60-63.
[10]张丽,梁中琴,顾振纶.姜黄素对内皮细胞的保护作用及机制研究[J].中国药理 通讯,2003;20(2):56.
[11]Amaswami G,Chai H,Yao Q,et al.Cureum in block hompcusteine-induced endothelial dysfunction in porcine coronaary arteries[J].J Vase surg,2004;40(6):1216-1222.
[12]Soni KB,Kuttan R.Indian Jphysiol Pharmacol,1992;36(4):273-279.
[13]温彩霞,许建华,黄秀旺.姜黄素在小鼠体内各脏器的药代动力学研究[J].中药药理与临床,2007;(4):1878-1881
[14]Ekstedt M,Franzen LE,Mathiesen ML,et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes[J].Hepatology,2006;44(4):865-871.
[15]谭德安,府伟灵,周智广,等.姜黄素治疗大鼠非酒精性脂肪肝病的实验研究[J].重庆医学,2007;(16):1026-1028.
[16]Suryanarayana P,Saraswat M,Krishna TP,et al.Curcumin andturmeric delay streptozotocin-induced diabetic cataract in rats[J].Investigative Ophthalmology&Visual Science,2005;46(6):2092-2099.
[17]Farhangkhoee H,Khan ZA,Chen S,et al.Differential effects of curcumin on vasoactive factors in the diabetic rat heart[J].Nutrition & Metabolism,2006;3:27-35.
[18]Kumar PA,Suryanarayana P,Reddy PY,et al.Modulation ofα-crystallin chaperone activityin diabetic rat lens by curcumin[J].Molecular Vision,2005;11:561-568.
[19]Srinivasan M.Effect of curcumin on blood sugar as seen in a diabetic subject[J].Indian J Med Sci,1972;26(4):269-270.
[20]Arun N,Nalini N.Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats[J].Plant Foods Hum Nutr,2002;57(1):41-52
[21]MaheshT,Balasubashini MS,Menon VP.Effect of photo-irradiated curcumin treatment against oxidative stress in streptozotocin-induced diabetic rats[J].J Med Food,2005;8(2):251-255.
[22]Babu PS,Srinivasan K.Hypolipidemic action of curcumin,the active principle of turmeric(Curcuma longa) in streptozotocin induced diabetic rats[J].Mol Cell Biochem,1997;166(1-2):169-175.
[23]Kuroda M,Mimaki Y,Nishiyama T,et al.Hypoglycemic effects of turmeric(Curcuma longal,rhizomes) on genetically diabetic KK-Ay mice[J].Biol Pharm Bull,2005;28(5):937-939.
[24]郭颖,高毅,刘永光.免疫抑制剂姜黄素逆转胰岛素抵抗的研究[J].中山大学学报(医学科学版),2007;(5):481-484.
[25]SHARMA S,CHOPRA K,KMLKARNI S K,et al.Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CDS0 co-stimulatory pathway[J].Clin Exp Immunol,2007;147(7):155-163.
[26]Jagetla GC,Aggarwal B."Spicing Up"of the Immune System by Curcumin[J].J Clin Immunol,2007:27(7):19-35.
[27]Jain SK,Rains J,Jones K.Effect of curcumin on protein glycosylation,lipid peroxidation,and oxygen radical generation in human red blood cells exposed to high glucose levels[J].Free Radic Biol Med,2006;41(1):92-96.
[28]Sajithlal GB,Chithra P,Chandrakasan G.Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats[J].Biochem Pharmacol,1998;56(12):1607-1614.
[29]Farhangkhoee H,Khan ZA,Chen S,et al.Differential effects of curcumin on vasoactive factors in the diabetic rat heart[J].Nutr Metab(Lond),2006;27(3):1-8.
[30]孙秀才,冯建章,裴晓阳,等.姜黄素对食高脂饲料家兔血管内皮功能的保作用.岭南心血管病杂志,2004;10(1):60-63.
[31]史立宏,王守训,高尔.核因子-κB的活化与动脉粥样硬化的启动.中国病理生理杂志,2003;19(11):1527-153.
[32]Wilson SH,BestPJ,EdwardsWD,et al.Nuclear factor-kap-paB immunoreactivity is present in human coronary plaque and enhanced in patientswith unstable angina pectoris.Atherosclereosis,2002;160(1):147-153.
[33]Bharti AC,Donato N,Sing S,et al.Curcumin(diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa Balpha kinase in human multiplemyeloma cells,leading to suppression of proliferation and induction of apoptosis.Blood,2003;101(3):1053-1062.
[34]周志斌,郭毅,王思鸿,等.基质金属蛋白酶9及转化生长因子β1在人动脉粥样硬化斑块的表达及其与斑块稳定性的关系.中国动脉硬化杂志,2006;14(3):217-220
[35]赵志光,谢丽微,王宗敏,等.浙江省温州市中医院ICU.姜黄素抗兔动脉粥样硬化作用的研究[J].浙江中西医结合杂志,2008;(2).67-68,76.
[36]梁萍,孙雷,唐建武.VCAM-1、ICAM-1和TNF-α在人动脉粥样硬化病灶中的表达及意义[J].中国动脉硬化杂志,2004;12(4):427-429.
[37]AmaswamiG,ChaiH,YaoQ,et al.Curcumin blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries[J].J Vasc Surg,2004;40(6):1216-1222.
[38]Li J,Perella MA,Tsai TC.Induction of vascular endothelial growth factor gene expression by interleukin-βin rataortic smoothmuscle cell[J].JBiol Chem,1995;270(1):308-313.
[39]董劭壮,赵水平,吴智鸿,等.姜黄素对兔皮下脂肪细胞脂联素分泌的影响[J].医学临床研究,2007;(8):1297-1300.
[40]Zheng S,Chen A.Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro[J].Biochem J,2004;384(Pt 1):149-157.
[41]Kuroda M,Mimaki Y.Hypoglycemic effects of turmeric(Curcuma longa L.rhizomes)on genetically diabetic KK-Ay mice[J].Biol Pharm Bull,2005;28(5):937-939.
[42]Woo H M,Kang J H,Kawada T,et al.Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes[J].Life Sci,2007;80(10):926-931.
[43]王春彬,高大中,殷跃辉,等.姜黄素对高脂血症兔主动脉NF-κB、VCAM-1、VEGF表达的影响[J].中成药,2007;(8):1127-1129.
[44]Gukovsky I,Reyes CN,Vaquero EC,et al.Curcumin ameliorates ethanol and nonethanol experimental pancreatitis[J].Am J Physiol Gastrointest Liver Physiol,2003;284(1):G85-95.
[45]Natarajan C,Bright JJ.Curcumin inhibits experimental allergic encephalo-myelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes[J].J Immunol,2002;168(12):6506-6513.
[46]Araujo CAC,Leon LL.Biological activities of Curcuma longa L[J].Mem Inst Oswaldo Cruz,2001;96(5):723-728.
[47]鲍华英,陈荣华,黄松明,等.姜黄素抑制脂多糖刺激的系膜细胞增殖及其白细胞介素1β和巨噬细胞趋化蛋白1基因的表达.临床儿科杂志,2003;41(11):822-826.
[48]麦国丰,简燕婷,杨玉捷,等.姜黄素对肠炎大鼠肠黏膜基质金属蛋白酶-9的调控[J].第四军医大学学报,2005;26(14):1257-1260.
[49]王建军,王三萍,熊海金.姜黄素对哮喘大鼠气道炎症与核因子B表达的影响.中国临床康复,2005;9(11):102-104.
[50]UkilA,Maity S,Karmakar S,et al.Curcumin,the major component of food flavour turmeric,reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis[J].Br J Pharmacol,2003;139(2):209-314.
[51]Zhang M,Deng CS,Zheng JJ,et al.Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis[J].Acta Pharmacol Sin,2006;27(8):1071-1077.
[52]Hisanori Y,Kentaro H,Kiyoshi K,et al.Inhibitory effect of curcumin on mammalian phospholipaseD activity.FEBS Letters,1997;417:196-198.
[53]Literat A,Su F,Norwicki M,et al.Regulation of pro-inflammatory cytokine expression by curcumin in hyaline membrane disease(HMD)[J].Life Sci 2001;70(3): 253-267.
[54]鲍华英,陈荣华,潘晓勤,等.姜黄素对脂多糖诱导的系膜细胞单核细胞趋化蛋白1基因及蛋白表达的影响.南京医科大学学报(自然科学版),2003;23(6):536-539.
[55]Tomita M,Holman BJ,Santoro CP.Astrocyte production of the chemokine macrophage inflammatory protein-2 is inhibited by the spice principle curcumin at the level of gene transcription[J].J Neutoinflammation,2005;2(1):8-12.
[56]Molnar V,Garai J.Plant-derived ant-inflammatoty compounds affect MIF tautomerase activitvy[J].Int Immunopharmacol,2005;5(5):849-56.
[57]Lee SL,Huang WJ,Lin WW et al.Preparation and anti-inflammatory activities of diarytheptanoid and diarytheptylamine analogs[J].Bioorg Med Chem,2005;13(22):6175-6181.
[58]Xu G,Huans W,Zhang WM et al.Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis [J].Di Yi Jun Yi Da Xue Xue Bao,2005;25(1):45-52.
[59]Deodhar SD.Preliminary study on antirheumatic activity of curcumin(diferuloylmethane)[J].India JMedRes,1980;71:632-633.
[60]B Lal,AK Kapoor,OP Asthana,et al.Efficacy of curcumin in the management of chronic anterior uveitis.Phyother Res,junel,1999;13(4):318-322.
[61]Reddy AC,Lokesh BR.Effect of Curcumin and eugenol on iron-induced hepatic toxicity in rats[J].Toxicology,1996;107(1):39-44.
[62]SreeJayan,Rao MN.Curcuminoids as potent inhibitors of lipid peroxidation[J].J Pharm Pharmacol,1994;46(12):1013-1019.
[63]Punithavathi D,Venkatesan N,Babu M.Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats[J].Br J Pharmacol,2000;131:169-172.
[64]Okada K,Wangpoengtrakul C,Tanaka T,et al.Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injure in mice.J Nutr,2001;131(8):2090-2095.
[65]Rezzani R,Rodella L,BufToli B,et al.Change in Renel Heme Oxygenase Expression in Cyclosporine A-induced Injury(J.Journal of Histochemistry and Cytochemut}y,2005;53(1):105-112.
[66]Costa MC,Castro I,Neto ALC.Cyclosporin contribute to nephrotoxicity;role for Ca~(2+)and Mg~(2+) ions[J].Dephrol Dial Transplant,2003;18:2262-2268.
[67]Motterlini R,Foresti R,Bassi R,et al.Curoumin,an antioxidant and anti-inflammatory agent,induces heme oxygenese-1 and protects endothelial cells against oxidative stress[J].Free and Medicine,2000,28(8):1303-1312.
[68]刘慎微,付艳红.姜黄素对大鼠环孢素肾毒性的防治作用.中阅药师,2007;10(5):419-422.
[69]龙明智,陈磊磊.姜黄素的药理作用.国外医学中医中药分册,2003;25(5):270-273.
[70]Jones EA,Shahed A,ShoskesDA,eta.Modulation of apoptotic and inflammatory genes by bioflavonoids and angiotensin Ⅱ inhibition in ureteral obstruction[J].Urology,2000;56(2):346-351.
[71]陈华,薛常镐,陈铁辉,等.姜黄及姜黄素对微囊藻粗毒素致急性肝损伤的化学预防作用[J].中国药理学通报,2005;21(12):1517-1519.
[72]Palojokie,Saraste A,Eriksson A,et al.Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction inrats[J].Am J Physiol Heart Circ Physiol,2001;280(6):H2726-H2731.
[73]黄维义,张英,严丽,等.血红素氧合酶-1高表达抗兔心肌缺血再灌注损伤研究.中国现代医学杂志,2006;16(10):1477-1479.
[74]Jeong GS,OH GS,Pae HO,et al.Comparative effects of curcuminoids on endothelial heme oxygenase-1 expression:ortho-methoxy groups are essential to enhance heme oxygenase activity and protection[J].Exp Mol Med,2006;31;38(4):393-400.
[75]Scapagnini G,Colombrita C,Amadio M,et al.Curcumin activates defensive genes and protects neurons against oxidative stress[J].Antioxid Redox Signal,2006;8(3-4):395-403.
[76]Tourkina E,Gooz P,Oates JC,et al.Curcumin-induced apoptosis in scleroderma lung fibroblasts:role of protein kinase cepsilon[J].Am J Respir Cell Mol Biol,2004;31(1):28-35.
[77]Mahmmoud YA.Curcumin modulation of Na~+,K~+-ATPase:phosphoenzyme accumulation,decreased K~+occu-lusion,and inhibition of hydrolytic activity[J].BrJ Pharmacol,2005;145(2):236-241.
[78]Sun M,Chen M,Dawood F,et al.Tumor necrosis factor-αmediates cardiac remodeling and ventricular dysfunction after pressure overload state[J].Circulation,2007;115(11):1398-1403.
[79]陈少伯,李玉明,姜铁明,等.姜黄素对充血性心衰兔心肌肿瘤坏死因子-α表达和心功能的影响[J].中华实用中西医杂志,2004;4(17):1418-1421.
[80]Jones EA,Shahod A,Shoskes DA,et al.Modulation of apoptoticand inflammatory genes by bioflavonoids and angiotensinⅡ inhibitionin ureteral obstruction[J].Urology,2000;56(2):346-351.
[81]刘润侠,党慧敏,段中琪,等.姜黄素防治慢性心力衰竭大鼠左心室胶原网络重 构的实验研究[J].中国中医急症,2006;15(1):70.
[82]Yang X,Thomas DP,Zhang X,et al.Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation[J].Arterioscler Thromb VascBiol,2006;26(1):85-90.
[83]林全,王良兴,周向锋,等.姜黄素防治慢性低O_2高CO_2大鼠肺动脉高压与C-Jun、C-Fos的关系研究[J].中国临床药理学与治疗学,2005;10(10):1118.
[84]徐丙发,吴华璞,祝晓光.姜黄素对大鼠缺血再灌注损伤的保护作用.蚌埠医学院学报,2007;32(60):637-639,封3.
[85]李军,曹红,连庆泉,等.姜黄素减轻沙土鼠海马CA1区脑缺血再灌注损伤与热休克蛋白表达变化的关系[J].温州医学院学报,2007;(4):317-321.
[86]张俊,周文祥,刘晓城,等.姜黄素对大鼠肾系膜细胞结缔组织生长因子表达的影响.华中科技大学学报(医学版),2006;35(1):99-102.
[87]宁勇,刘晓城.姜黄素对糖尿病大鼠肾脏保护作用的研究.湖北中医学院学报,2004;6(1):10-11.
[88]舒建昌,王红利,叶国荣,等.姜黄素治疗肝纤维化及相关细胞因子变化的研究[J].中药材,2007;(11):1421-1425.
[89]Zheng S,Chen A.Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells.Am J Physiol Gastrointest Liver Physiol,2007;292(1):113-123.
[90]舒建昌,何雅军,吕霞,等.姜黄素诱导肝星状细胞凋亡的相关分子机制的初步研究.中华消化杂志,2006;26(11):758-761.
[91]Ha H,Lee HB.Reactive oxygen species and matrix remodelingin diabetic kidney[J].J Am Soc Nephro,2003;14(8 Supp13):S246-249.
[92]李银生,牛建昭,王继峰,等.姜黄素对肺纤维化大鼠肺组织胶原沉积及转化生长因子β1表达的影响[J].中华中医药学刊,2007;25(1):55-57.
[93]汪海慧,成扬.姜黄素药理作用的研究进展.上海中医药大学学报,2007;21(96):73-76.
[94]苏凤菊,曾令兰,李淑莉,等.姜黄素对肝纤维化大鼠瘦素及瘦素受体表达的影响[J].中西医结合肝病杂志,2007;(4):225-226,229.
[95]王浩,付文成,王云满,等.姜黄素及氧化低密度脂蛋白对系膜细胞增殖和凋亡的影响[J].上海医学,2007;(7):145-147.
[96]刘慎微,熊礼佳,付艳红.姜黄素对2型糖尿病大鼠肾脏改变的影响[J].医药导报,2007;26(7):749-753.
[97]Shishir S,Hesham M A,Raymond L,et al.Curcumin(diferuloylmethne) inhibits constitutive NF-κB activation,induces G1/S arrest,suppresses proliferation,and induces apoptosis in mantle cell lymphoma[J].Biochem Pharmacol,2005;70:700-713.
[98]彭文,李琦,付文成,等.姜黄素及OX-LDL对系膜细胞凋亡及FAP-1和bag-1表达的影响[J].上海中医药大学学报,2007;21(4):54-57.
[99]Jungy EM,Limy JH,Lee TJ,et al.Curcumin sensitizes umor necrosis factor related apoptosis inducing ligand TRAIL induced apoptosis through reactive oxygen species ediated upregulation of death receptor5(DR5)[J].Carcinogenesis,2005;26(11):1905-1913.
[100]邓刚,余建华,叶章群,等.姜黄素对雄激素非依赖性前列腺癌细胞PC-3及血管内皮生长因子的影响[J].中华男科学杂志,2008;(2):116-121.
[101]Liu Hong-qi,ChenYan,CuiGuo-hu,et al.Curcumin,a potent anti-tumor reagent,is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation[J].Acta pharmacological Sinica,2005:26(5):603-608.
[102]吕必华,张玲,朱长才,等.姜黄素抑制HepG2细胞HDAC1活性及促进P21-(WAF1/CIP1)表达的研究[J].中国中药杂志,2007;(19):2051-5055.
[103]刘波,白庆咸,陈协群,等.姜黄素对人多发性骨髓瘤细胞表达Survivin、Bcl-2、Bax的影响[J].中国实验血液学杂志,2007:(4):762-766.
[104]Moragoda L,Jaszewski R,Majumdar AP.Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells[J].Anticancer Res,2001;21(2A):873-878.
[105]Park,SD.Zedoariae rihzoma and curcumin inhibits platelet-der Vedgrowth factorinduced proliferation of human hepatic mypfibroblasts[J].Int Immunopharmacol,2005;5:555-569.
[106]梁斌,·黄美健,丁志山.脱甲氧基姜黄素对血管生成影响的实验研究[J].浙江中西医结合杂志,2008;(2):69-70.
[107]孙军,李岩.姜黄素对人肝癌细胞BEL-7402中HIF-1表达的影响[J].中国药理学通报,2006;22(11):1379-1383.
[108]Yang XP,Thoams P,Zhang XC,et al.Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation[J].Arterioscler ThrombVasc Biol,2006;26(1):85-90.
[109]Anuchapreeda S,Leechanachai P,Smith MM,et al.Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells[J].Biochem Pharmacol,2002;64
[110]Tang XQ,Bi H,Feng JQ,et al.Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR[J].Acta Pharmacol Sin,2005;26(8):1009-1016.
[111]英焕春,吕靖,张淑兰,等.姜黄素对卵巢癌耐药细胞株COC1/DDP的增敏作 用及其机制的研究[J].广西医科大学学报,2007;(3):361-364..
[112]高凤兰,李维山,任亮,等.姜黄素对马利兰耐药HL-60细胞生长的影响[J].中国现代医药杂志,2007;9(6):35-37.
[113]Sanjay Kumar,Upma Narain,Snehiata Tripathi,et al.Syntheses of curcumin bioconjugates and study of their antibacterial activities against β-lactanlase-producing microorganisms[J].Bioconjugate Chem,2001;12:464-469.
[114]胡小军,李凤侠.姜黄油抑菌作用的研究[J].食品研究与开发,2006;27(5):30-31.
[115]Koide T.姜黄素的体外杀利什曼原虫作用[英].Biol Pharm Bull,2002;25(1):131-133.
[116]Dalavaikodihalli NN,ViswanathanAN,Palakkod G,et al.Curcumin Artemisinin combination therapyfor malaria[J].Antimicrob Agents Chemother,2006;50(5):1859-1860.
[117]张永强,丁伟,赵志模,等.姜黄对朱砂叶螨生物活性研究[J].植物保护学报,2004;31(4):390-394.
[118]Shishir,MA Hesham,L Raymond,et al.Biochemical Pharmacology,2005;70(5):700-713.
[2]宗蕾,陆伦根.调血脂药与肝脏安全性.中国肝脏学,2008;13(6):510-512.
[3]张占柱.从痰、瘀、虚论治高脂血症[J].河南中医药学刊,1999;14(6):45-51.
[4]杨智敏.高脂血症的中医药治疗研究初探[J].现代医药卫生,2005;21(23):3241-3242.
[5]于克娇.中医对高脂血症的认识和治疗现状[J].中国航天工业医药,2000;(4):79-80.
[6]周美芳.从痰瘀论治高脂血症88例临床观察[J].贵阳中医学院学报,2005;27(1):43.
[7]熊原.加味半夏白术天麻汤治疗高血压并高脂血症的临床研究[J].河北中医,2005;27(10):751-752.
[8]陈苏宁,杨积武,张放,等.血府逐瘀汤加减治疗高脂血症100例[J].辽宁中医杂志,2001:28(6):364-365.
[9]陆新.加味天麻钩藤饮治疗高脂血症的临床观察.湖北中医杂志,2004;26(4):13-14.
[10]吕正有.中药降脂汤治疗高脂血症临床疗效观察[J].辽宁中医药大学学报,2008;4(10):98-99.
[11]王忠壮译.牛膝抗炎和抗高胆固醇血症成份的研究.国外医学植物药分册,1994;9(3):122.
[12]张馨木,曲绍春,睢大员,等.人参Rb组皂苷对高脂血症大鼠血脂代谢的影响及其抗氧化作用.中国中药杂志,2004;29(11):1085-1088.
[13]宋士军,李芳芳,尹智玮,等.何首乌对实验性高脂血症作用的研究.河北中医药学报,2003;18(4):27-28.
[14]高莹,肖颖.山楂及山楂黄酮提取物调节大鼠血脂的效果研究.中国食品卫生杂志,2002;14(3):14-16.
[15]董加喜,王梅娟.富含川芎嗪脂质体对实验性动脉粥样硬化家兔的降脂和抗氧化作用.中国中医药科技,1997;4(6):F003.
[16]刘宏雁.刺五加总皂甙对实验性高脂血症大鼠血脂的影响.白求恩医科大学学报,1995:21(4):34.
[17]李林,邢善国,周金黄.绞股蓝总皂甙对离体大鼠肝脏脂质过氧化及膜流动性损 伤的保护作用.中国药理学报,1991;7(5):342.
[18]裴莲花,吴学,金光洙.虎杖化学成分及药理作用研究现状.延边大学医学学报,2006;29(2):147-149.
[19]何菊英,刘松青.决明子的药理作用及其临床应用.药学实践杂志,2001;19(2):111-113.
[20]周利玲,吴和平,李树平,等.大黄素对鹌鹑脂质代谢的影响研究。怀化医专学报,2005;4(2):12-15.
[21]王金红,高尔.乳化葛根素对高脂血症家兔模型调血脂和抗氧化作用.潍坊医学院学报,2001;23(1):6.
[22]罗琼,李瑾玮,张声华.枸杞及其多糖对家兔血脂的影响.食品科学,1997;18(4):5.
[23]孙涛,王厚龙,孙凤发.灵芝的药用价值与栽培技术.人参研究,2007;(2):23-24
[24]陈凯,陈凤兰.中西医结合治疗高脂血症62例疗效观察[J].新中医,2006;38(1):58.
[25]赵峥,范中有.中西医结合治疗高脂血症127例疗效观察[J].四川中医,2005;23(10):56.
[26]冯蓉.中西医结合治疗高脂血症56例临床观察[J].四川中医,2005;23(1):56.
[27]杨云,张晶,陈玉婷.天然药物化学成分提取分离手册(修订版).中国中医药出版社,2003:584
[28]Tonnesen HH,Masson M,Loftsson T.Studies of curcumin and curcuminoids ⅩⅩⅦ.Cyclodextrin complexation:Solubility,chemical and photochemical stability[J].Int J Pharm2002;(244):127.
[29]沃兴德,崔小强,唐利华.姜黄素对食饵性高脂血症大鼠血浆脂蛋白代谢相关酶活性的影响[J].中国动脉硬化杂志,2003;7(4):339-341.
[30]Fan Chunlei,Qian Ying,Wo Xingde,et al.Effect of Curcumin on the Gene Expression of Low Density Lipoprotein Receptors[J].Chin J Integr Med,2005;11(3):201-204.
[31]窦晓兵,范春雷,洪行球,等.姜黄素对人淋巴细胞人低密度脂蛋白受体表达影响的研究[J].中国药学杂志,2005;40(13):980-982.
[32]Babu PS et al.Hypolipidemic action of curcumin,the active principle of turmeric (CurcuminLonga) in streptozotoc ininduced diabetic rats[J].Mol-Cell-Biochem,1997;166(1-2):169-175.
[33]沃兴德,洪行球,高承贤,等.姜黄素长期毒性实验.浙江中医学院学报,2000;24(1):61-64.
[34]王舒然,陈炳卿,孙长颢.姜黄素对大鼠调血脂及抗氧化作用的研究[J].卫生研究,2000;29(4):241
[35]沃兴德.姜黄素对低密度脂蛋白和脂蛋白(a)代谢的影响[J].中国动脉硬化杂志,1999;7(4):33.
[36]潘赞红,李薇,金鑫.姜黄素对高脂血症动物的实验研究[J].天津中医,1999;16(5):35.
[37]孙秀才,冯建章,斐晓阳,等.姜黄素对食高脂饲料家兔血管内皮功能的保护作用[J].岭南医学杂志,2004;10(1):60-63.
[38]张丽,梁中琴,顾振纶.姜黄素对内皮细胞的保护作用及机制研究[J]中国药理通讯,2003:20(2):56.
[39]Amaswami G,Chai H,Yao Q,et al.Curumin block hompcusteine-induced endothelial dysfunction in porcine coronaary arteries[J].J Vase surg,2004;40(6):1216-1222.
[40]王政,惠伯棣,裴凌鹏,等.大鼠体内类姜黄素的组成变化.食品科学,2007;28(9):542-545.
[41]王旗,王夔.姜黄素的代谢研究[J].中国药理学通报,2003;19(10):1097-1102.
[42]Holder GM,Plummer JL,Ryan AJ.The metabolism and excretion of curcumin(1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat.Xenobiotica,1978;8(12):761-768.
[43]Ravindranath V,Chandrasekhara N.Absorption and tissue distribution of curcumin in rats.Toxicology,1980;16(3):259-265.
[44]许汉林,孙芸,邵继征,等.姜黄素脂质体在大鼠体内药代动力学研究[J].湖北中医学院学报,2007;(1):42-43.
[45]韦晓瑜,陈世忠.姜黄素注射液在大鼠体内的药代动力学[J].北京大学学报(医学版),2003;35(3):230.
[46]Pan MH,Huang TM,Lin JK,et al.Biotransformation of curcumin through reduction and glucuronidation in mice[J].Drug Metab Dispos,1999;27(4):486-491.
[47]温彩霞,许建华,黄秀旺.姜黄素在小鼠体内各脏器的药代动力学研究[J].中药药理与临床,2007;(4):25-26.
[48]Pan MH,Huang TM,Lin JK.Biotransformation of curcumin through reduction and glucuroni dation in mice.Drag Metabolitism & Disposition,1999;27(4):486-494.
[49]Cheng AL,Hsu CH,Lin JK.Phase I clinical trial of curcumin,a chemopreventive agent,in patients with high-ris kor pre-malignant lesions.Anticancer Res,2001;21:2895-2900.
[50]Ruffin MT,Normolle DP,Heath DD.Dose escalation of curcumin in healthy adults,CancerEpidem Biomar Prevent,2003;12:1324-1340.
[51]Sharma RA,MC Lell.,Hill KA.Pharmacodynamic and Pharmacokinetic study of oral curcuma extract in patients with colorectal cancer.Clin Cancer Res,2001;7:1894-1900.
[52]Ireson CR,Jones D,Orr S,et al.Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine[J].Cancer Epidemiol Biomarkers Prev,2002;11(1):105-111.
[53]Shoba G,Joy D,Joseph T,et al.Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers[J].Planta Medica,1998;64:353-356.
[54]Tonnesen HH,Masson M,Loftsson T.Studies of curcumin and curcuminoids ⅩⅩⅦ.Cyclodextrin complexation:Solubility,chemical and photochemical stability[J].Int J Pharm,2002;(244):127-132.
[55]Lee SA,Hong SS,Han XH,et al.Piperine from the fruits of piperlongum with inhibitory effect on monoamine oxidase and antide-pressant-like activity[J].Chem Pharm Bull(Tokyo),2005;53(7):832-836.
[56]Bajad S,Bedi KL,Singla AK,et al.Antidiarrhoeal activity of piperine in mice[J].Planta Med,2001;67(3):284-288.
[57]Szolcsanyi J,Bartho L.Capsaicin-sensitive afferents and their role in gastroprotection:an update[J].J Physiol Paris,2001;95(1-6):181-186.
[58]Morikawa T,Matsuda H,Yamaguchi I,et al.New amides and gas-tro protective constituents from the fruit of piperchaba[J].Planta Med,2004;70(2):152-157.
[59]于腾飞,刘屏,王东晓,等.胡椒碱对过氧化氢损伤大鼠心肌线粒体的保护作用及机制研究.解放军药学学报,2008;24(1):7-9.
[60]白永忠.胡椒碱对兔实验性动脉粥样硬化的预防作用.中国民族医药杂志,2002;8(3):35-36.
[61]包兰兰,金桩.胡椒碱降血脂作用的实验研究.中国民族医药杂志,2004;(1):22-23
[62]Vijayakumar RS,Surya D,Nalini N.Antioxidant efficacy of black pepper(Piper nigrum L.)and piperine in rats with high fat diet induced oxidative stress[J].Redox Rep,2004;9(2):105-109.
[63]Mittal R,Gupta RL.In vitro antioxidant activity of piperine[J].Methods Find Exp Clin Pharmacol,2000;22(5):271-276.
[64]李月廷,王海梅,吴恩,等.胡椒酸甲酯对大鼠血清胆固醇的调整作用及机理.中草药,1993;24(1):27-29.
[65]Dogra RK,Khanna S,Shanker R.Immunotoxicological effects of piperine in mice[J].Toxicology,2004;196(3):229-233.
[66]海英,那生桑,双福,等.荜茇胡椒碱致畸试验研究.世界科学技术-中医药现代化,2008;10(1):133-137
[67]R M otterlini,R Foresti,R Bassi,et al.Curcumin,an antioxidant and anti-inflammatory agent,induces heme oxygenase-land protects endothelial cells against oxidative stress[J].Free Radic BiolMed,2000;28(8):1303-1307.
[68]Shoba G,Joy D,Joseph T,et al.Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.Planta Medica,1998;64:353-358.
[69]Sujata MK,Priyadarsini KI,Palit DK,et al.Effect of Solvent on the Excited-state photophysical properties of curcumin[J].PhotochemPhotobiol,2000;72(5):625-631.
[70]Barik KA,Priyadarsini,Hari Mohan.Photophysical studies on binding of curcumin to bovine serum albumin[J].PhotochemPhotobiol,2003;77(6):597-602.
[71]Erika Pfeiffer,Simone Hohle,Aniko MS,et al.Studies on the stability of turmeric constituents[J].J of Food Engineering,2003;56:257-263.
[72]Bhardwaj RK,Glaeser H,Becquemont L,et al.Piperine,a major constituent of black pepper,inhibits human P-glycoprotein and CYP3A4[J].J Pharmacol Exp Ther,2002;302(2):645-649.
[73]Gupta SK,Bansal P,Bhardwaj RK.Comparativeanti-nociceptive,anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination[J].Pharmacol Res,2000;41(6):657-661.
[74]Hiwale AR,Dhuley JN,Naik SR.Effect of co-administration of piperine on pharmacokinetics of beta-lactam antibiotics in rats[J].Indian J Exp Biol,2002;40(3):277-281.
[75]Velpandian T,Jasuja R,Bhardwaj RK,et al.Piperine in food:inter-ference in the pharmacokinetics of phenytoin[J].Eur J Drug Metab Pharmacokinet,2001;26(4):241-246.
[76]Khajuria A,Thusu N,Zutshi U.Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics:influence on brush border membrane fluidity,ultra-structure and enzyme kinetics[J].Phyto Medicine,2002;9(3):224-230.
[1]王春彬,高大中.姜黄素的研究进展以及在心血管疾病中的应用.心血管病学进展,2005;26(6):614-616.
[2]Pan MH,Huang TM,Lin JK.Biotransformation of curcumin through reduction and glucuronidation in mice.Drug Metabolitism & Disposition,1999;27(4):486-494.
[3]Ireson C.R.,Jones D.J.L,Orr S.Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine.Cancer Epidem Biomar Prevent,2002;(11):97-104.
[4]曾苏.加强药学领域中药物代谢的研究.浙江大学学报(医学版),2008;37(2):109-113.
[5]刘磊,邓敏,高人焘,等.几种药物对HepG2细胞MRP2表达的影响[J].实用肝脏病杂志,2006;9(6):333-336.
[6]关溯.Caco-2细胞模型一药物吸收研究的有效工具[J].中国药理学通报,2004;20(6):609-613.
[7]刘昌孝.中药药代动力学研究的难点和热点.药学学报,2005;40(5):398.
[8]高坤,孙进,何仲贵.Caco-2细胞模型在口服药物吸收研究中的应用.沈阳药科大学学报,2005;22(62):479-484.
[9]Cheng Y.姜黄素降低结肠癌Caco-2细胞中酸性神经鞘磷酯酶活性.国外医药·植物药分册,2008;23(4):181-182.
[10]Nishimura N.Effects of Chinese herbal medicines on intestinal drug absorption.YakugakuZusshi,2005;125(4):363-369.
[11]WANG Y,CAO J,ZENG S.Involvement of P.glycoprotein in regulating cellular levels of Ginkgo flavonols:quercetin,kaempferol,and isorhamnetinfJ].J P Pharmaeof,2005;57(6):751-758.
[12]GUAN S,BI H C,CHEN X,et al.Transport mechanism of totanshinone across Caco-2 monolayer model.ClinPharmax'ol(中国临床药理学杂志),2005:21(4):268-271.
[13]Zheng Y,Yang XW,J Chin Integr Med.Zhong Xi Yi Jie He Xue Bao,2008:6(7):704-710
[14]Kato M,Chiba K,Horikawa M,et al.The quantilative prediction of in vivo enzyme induction caused by drug exposure from in vitro information on human hepatocytes [J].Drug Metab Pharmacokinet,2005;(20):236.
[15]张文军,娄建石,董伟林,等.布洛芬在损伤后原代培养大鼠肝细胞中代谢的研究.中国药学杂志,2008;43(6):472-474
[16]蔡燕,戚新明,宫丽崑,等.汉防已甲素诱导大鼠原代肝细胞线粒体途径的凋亡:依赖于caspase和由Endonuclease G(Endo G)介导的不依赖于caspase的凋亡途径.毒理学杂志,2005:19(3):219-220
[17]李素婷,姜凌雪,周晓慧,等.柴胡皂苷d对乙醇损伤原代培养大鼠肝细胞的保护作用及其机制研究.时珍国医国药,2008;19(11):2752-2753
[18]谭洪玲,杨明会,王宇光,等.大鼠原代肝细胞培养方法的建立.中国应用生理学杂志,2006:22(4):509-512
[19]Shibata Y.Takahashi H.Ishil Y.A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocyts suspended in serum.Drug metab and dispos,2000;28:15-18.
[20]Annaert P.Brower KR.Assessment of drug in]eractions in hepatobiliary transport using rhodaminel 23 in sandwich cultured rat hepatocytes[J].Drug metab and dispos,2005;33:388.
[21]Hariparsad N,Sane RS,Strom SC,et al.In vitro methods in human drug biotransformation research:implications for cancer chemotherapy.Toxicology in Vitro,2006;20:135.
[22]徐哲,白雪帆.腾光菊,等.微载体黏附培养SD大鼠肝细胞的生物学特性.第四军医大学学报,2004;25(5):135.
[23]Seglen PO.Preparation of rat liver cells I,effect of Ca~(2+) on enzymatic dispersion of isolated perfused liver[J].Exp Cell Res,1972;74:450-455.
[24]贾珍容,邱银生,王大菊,等.比较两种消化酶对分离大鼠肝细胞的影响.中国药师,2006;9(7):590-593
[25]庄鹏,李志莹,范紫香,等.改良原代大鼠肝细胞的体外分离培养和功能研究.热带医学杂志,2008;8(10):1024-1027.
[1]许汉林,孙芸,邵继征,等.姜黄素脂质体在大鼠体内药代动力学研究[J].湖北中医学院学报,2007;9(1):42-43.
[2]刘安昌,娄红祥,赵丽霞.姜黄素药理活性及体内代谢[M].国外医学:植物药分册,2004;19(1):1-5.
[3]王旗,王夔.姜黄素的代谢研究[J].中国药理学通报,2003;19(10):1097-1012.
[4]张继芬,侯世祥,刘惠莲,等.小鼠血浆中姜黄素的含量测定及药动学研究[J].中国药学杂志,2007;42(4):288-290.
[5]刘安昌,娄红祥,赵丽霞.姜黄素在大鼠体内的代谢研究[J].上海中医药杂志,2008;42(8):74-77.
[6]陆兔林,毛春芹,卞慧敏,等.莪术中姜黄素在大鼠体内的药动学研究[J].中草药,2005;36(8):1157-1158.
[7]韩刚,张义春,刘士勇,等.姜黄中姜黄素含量测定方法的比较[J].西北药学杂志,2005;20(1):15-16.
[8]刘晓亮,张宇,孙蕴哲,等.水飞蓟宾脂质微球的制备及在大鼠体内的药物动力学考察.沈阳药科大学学报,2008;25(6):423-428.
[9]许汉林,孙芸,邵继征,等.姜黄素脂质体在大鼠体内药代动力学研究[J].湖北中医学院学报,2007;(1):42-43.
[10]Shoba G,Joy D,Joseph T,et al.Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers[J].Planta Medica,1998;64:353-356.
[1]高敏,淤泽溥,赵远,等.用Triton WR-1339复制小鼠高脂血症动物模型的研究.云南中医中药杂志,2008,29(6):46-47.
[2]刘明,董超仁,苏静怡.一种简易大鼠高脂血症模型[J].中国药理学通报,1989;5(2):119-120.
[3]徐叔云,卞如濂,陈修,等.药理实验方法学.人民卫生出版社,2003;第三版:1319.
[4]王倩,汪海.新化合物哌芳安他对兔和鹌鹑高脂血症性脂肪肝的影响.中国药理学通报,2003;19(12):1349-1353.
[5]方叶青,杨天伦,陈小彬.血脂比值和单项血脂与冠脉狭窄程度的相关分析.湘南学院学报(医学版),2006;8:7-8.
[6]Cleeman JI.Executive summary of the third report of the national cholesterol education program(NCEP)expert panel on detection,evaluation,and treatment of high blood cholesterol in adults(adults treatment panelⅢ)[J].JAMA,2001;285:2486-2497.
[7]蒋宪成,庄庆祺,梅美珍.卵磷脂胆固醇酰基转移酶活性的简易测定法.上海第一医学院学报,1985,12(2):259.
[8]王伯远,李坟松,黄高异,等主编.组织的取材和固定方法.病理学技术,人民卫生出版社,2000:74.
[9]王伯远,李坟松,黄高异,等主编.染色基石原理、生物染料和苏木精-伊红染色方法.病理学技术,人民卫生出版社,2000:30-132.
[1]王政,惠伯棣,裴凌鹏,等.大鼠体内类姜黄素的组成变化.食品科学,2007;28(9):542-545.
[2]Ireson C R,JonesD JL,OrrS,et al.Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine[J].Cancer Epidemiol Biomarkers Prey,2002;11(1):105-111.
[3]王春彬 综述 高大中.姜黄素的研究进展以及在心血管疾病中的应用.心血管病学进展,2005;26(6):614-616.
[4]Pan MH,Huang TM,Lin JK.Biotransformation of curcumin through reduction and glucuronidation in mice.Drug Metabolitism & Disposition,1999;27(4):486-494.
[5]ShobaG,Joy D,Joseph T,et al.Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers[J].Planta Medica,1998;64:353-356.
[6]杨海涛,王广基,Caco-2单层细胞模型及其在药学中的应用[J].药学学报,2000;35(10):797-800.
[7]Jumarie C,Malo C.Caco-2 cells cultured in serum free medium as a model for the study of enterocytic differentiation in vitro[J].J Ce Ⅱ Physiol,1991;149(1):24-33.
[8]Artursson P,Karlsson J.Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial(Caco-2)cells[J].Biochem Biophys Res Commun,1991;175(3):880-885.
[9]Westphal K,Weinbrenner A,Zschiesche M,et al.Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings:A new typeof drug /drug interaction[J].Clin Pharmacol Ther,2000;68(4):345-355.
[10]Hiroshi S,Yuichi S.Role of metabolic enzymes and ef-flux transporters in the absorption of drugs from the small intestine[J].Eur J Pharm Sci,2000;12(1):3-12.
[11]Phung-Ba V,Wamery A,Scherman D,et al.Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells[J].Eur J Pharmacol,1995;288(2):187-192.
[12]Hunter J,Jepson M A,Tsuruo T,et al.Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells[J].J Biol Chem,1993;268(20):14991-14997.
[13]薛俊峰,李桦,阮金秀,等.氮烯乙茶在成年大鼠肝细胞中的生物转化[J].药学学报,1999;34(10):739.
[14]贾珍容,邱银生,王大菊,等.比较两种消化酶对分离大鼠肝细胞的影响.中国药师,2006:9(7):590-593.
[15]包晓华,巴根那,白明纲,等.HPLC法测定协日嘎四味片中姜黄素类成分的含量. 中国民族医药杂志,2009;1:42-44.
[16]崔红彬,孟建升,蒋俊春,等.HPLC法测定姜黄片中姜黄素的含量.中国药师,2008;11(9):1071-1072.
[17]Ravindranath V,Chandrasekhara N.Absorption and tissue distribution of curcumin in rats.Toxicology,1980;16(3):259-265.
[18]许汉林,孙芸,邵继征,等.姜黄素脂质体在大鼠体内药代动力学研究[J].湖北中医学院学报,2007;9(1):42-43.
[19]Kris-Etherton PM and D iteschy J.Design criteria for studies examing individual fatty acid effects on cardiovascular disease risk factors:human and animal studies.Am J Clin Nutr,1997;65(1):1594-1598.
[20]王威,江海涛,李玉红,等.小鼠、大鼠高甘油三酯血症、脂肪肝模型的比较.天津中医药,2006;47(7):192-194.
[21]刘明,董超仁,苏静怡.一种简易大鼠高脂血症模型[J].中国药理学通报,1989;5(2):119-120.
[22]何峰,邵海琳,林展增,等.血脂及血清载脂蛋白A I、B测定对冠心病诊断的意义.河北北方学院学报·医学版,2005;22(6):34-35.
[23]郭虹,陈在嘉,徐义枢.血清脂质与脂质过氧化关系的临床研究.中国循环杂志,1999;6(5):373-375.
[1]沃兴德,崔小强,唐利华.姜黄素对食饵性高脂血症大鼠血浆脂蛋白代谢相关酶活性的影响[J].中国动脉硬化杂志,2003;7(4):339-341.
[2]Fan Chunlei,Qian Ying,Wo Xingde,et al.Effect of Curcumin on the Gene Expression of Low Density Lipoprotein Receptors[J].Chin J Integr Med,2005;11(3):201-204.
[3]窦晓兵,范春雷,洪行球,等.姜黄素对人淋巴细胞人低密度脂蛋白受体表达影响的研究[J].中国药学杂志,2005:40(13):980-982.
[4]Babu PS.Hypolipidemic action of curcumin,the active principle of turmeric(Curcumin Longa) in streptozotoc ininduced diabetic rats[J].Mol-Cell-Biochem,1997;166(1-2):169-175.
[5]沃兴德,洪行球,魏佳萍,等.姜黄醇提取物对高脂血症患者脂代谢及肝肾功能的影响[J].浙江中医学院学报,1999;23(1):2022.
[6]王舒然,陈炳卿,孙长颢.姜黄素对大鼠调血脂及抗氧化作用的研究[J].卫生研究,2000:29(4):241.
[7]沃兴德.姜黄素对低密度脂蛋白和脂蛋白(a)代谢的影响[J].中国动脉硬化杂志,1999;7(4):33.
[8]潘赞红,李薇,金鑫.姜黄素对高脂血症动物的实验研究[J].天津中医,1999;16(5):35.
[9]孙秀才,冯建章,斐晓阳,等.姜黄素对食高脂饲料家兔血管内皮功能的保护作用[J].岭南医学杂志,2004;10(1):60-63.
[10]张丽,梁中琴,顾振纶.姜黄素对内皮细胞的保护作用及机制研究[J].中国药理 通讯,2003;20(2):56.
[11]Amaswami G,Chai H,Yao Q,et al.Cureum in block hompcusteine-induced endothelial dysfunction in porcine coronaary arteries[J].J Vase surg,2004;40(6):1216-1222.
[12]Soni KB,Kuttan R.Indian Jphysiol Pharmacol,1992;36(4):273-279.
[13]温彩霞,许建华,黄秀旺.姜黄素在小鼠体内各脏器的药代动力学研究[J].中药药理与临床,2007;(4):1878-1881
[14]Ekstedt M,Franzen LE,Mathiesen ML,et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes[J].Hepatology,2006;44(4):865-871.
[15]谭德安,府伟灵,周智广,等.姜黄素治疗大鼠非酒精性脂肪肝病的实验研究[J].重庆医学,2007;(16):1026-1028.
[16]Suryanarayana P,Saraswat M,Krishna TP,et al.Curcumin andturmeric delay streptozotocin-induced diabetic cataract in rats[J].Investigative Ophthalmology&Visual Science,2005;46(6):2092-2099.
[17]Farhangkhoee H,Khan ZA,Chen S,et al.Differential effects of curcumin on vasoactive factors in the diabetic rat heart[J].Nutrition & Metabolism,2006;3:27-35.
[18]Kumar PA,Suryanarayana P,Reddy PY,et al.Modulation ofα-crystallin chaperone activityin diabetic rat lens by curcumin[J].Molecular Vision,2005;11:561-568.
[19]Srinivasan M.Effect of curcumin on blood sugar as seen in a diabetic subject[J].Indian J Med Sci,1972;26(4):269-270.
[20]Arun N,Nalini N.Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats[J].Plant Foods Hum Nutr,2002;57(1):41-52
[21]MaheshT,Balasubashini MS,Menon VP.Effect of photo-irradiated curcumin treatment against oxidative stress in streptozotocin-induced diabetic rats[J].J Med Food,2005;8(2):251-255.
[22]Babu PS,Srinivasan K.Hypolipidemic action of curcumin,the active principle of turmeric(Curcuma longa) in streptozotocin induced diabetic rats[J].Mol Cell Biochem,1997;166(1-2):169-175.
[23]Kuroda M,Mimaki Y,Nishiyama T,et al.Hypoglycemic effects of turmeric(Curcuma longal,rhizomes) on genetically diabetic KK-Ay mice[J].Biol Pharm Bull,2005;28(5):937-939.
[24]郭颖,高毅,刘永光.免疫抑制剂姜黄素逆转胰岛素抵抗的研究[J].中山大学学报(医学科学版),2007;(5):481-484.
[25]SHARMA S,CHOPRA K,KMLKARNI S K,et al.Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CDS0 co-stimulatory pathway[J].Clin Exp Immunol,2007;147(7):155-163.
[26]Jagetla GC,Aggarwal B."Spicing Up"of the Immune System by Curcumin[J].J Clin Immunol,2007:27(7):19-35.
[27]Jain SK,Rains J,Jones K.Effect of curcumin on protein glycosylation,lipid peroxidation,and oxygen radical generation in human red blood cells exposed to high glucose levels[J].Free Radic Biol Med,2006;41(1):92-96.
[28]Sajithlal GB,Chithra P,Chandrakasan G.Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats[J].Biochem Pharmacol,1998;56(12):1607-1614.
[29]Farhangkhoee H,Khan ZA,Chen S,et al.Differential effects of curcumin on vasoactive factors in the diabetic rat heart[J].Nutr Metab(Lond),2006;27(3):1-8.
[30]孙秀才,冯建章,裴晓阳,等.姜黄素对食高脂饲料家兔血管内皮功能的保作用.岭南心血管病杂志,2004;10(1):60-63.
[31]史立宏,王守训,高尔.核因子-κB的活化与动脉粥样硬化的启动.中国病理生理杂志,2003;19(11):1527-153.
[32]Wilson SH,BestPJ,EdwardsWD,et al.Nuclear factor-kap-paB immunoreactivity is present in human coronary plaque and enhanced in patientswith unstable angina pectoris.Atherosclereosis,2002;160(1):147-153.
[33]Bharti AC,Donato N,Sing S,et al.Curcumin(diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa Balpha kinase in human multiplemyeloma cells,leading to suppression of proliferation and induction of apoptosis.Blood,2003;101(3):1053-1062.
[34]周志斌,郭毅,王思鸿,等.基质金属蛋白酶9及转化生长因子β1在人动脉粥样硬化斑块的表达及其与斑块稳定性的关系.中国动脉硬化杂志,2006;14(3):217-220
[35]赵志光,谢丽微,王宗敏,等.浙江省温州市中医院ICU.姜黄素抗兔动脉粥样硬化作用的研究[J].浙江中西医结合杂志,2008;(2).67-68,76.
[36]梁萍,孙雷,唐建武.VCAM-1、ICAM-1和TNF-α在人动脉粥样硬化病灶中的表达及意义[J].中国动脉硬化杂志,2004;12(4):427-429.
[37]AmaswamiG,ChaiH,YaoQ,et al.Curcumin blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries[J].J Vasc Surg,2004;40(6):1216-1222.
[38]Li J,Perella MA,Tsai TC.Induction of vascular endothelial growth factor gene expression by interleukin-βin rataortic smoothmuscle cell[J].JBiol Chem,1995;270(1):308-313.
[39]董劭壮,赵水平,吴智鸿,等.姜黄素对兔皮下脂肪细胞脂联素分泌的影响[J].医学临床研究,2007;(8):1297-1300.
[40]Zheng S,Chen A.Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro[J].Biochem J,2004;384(Pt 1):149-157.
[41]Kuroda M,Mimaki Y.Hypoglycemic effects of turmeric(Curcuma longa L.rhizomes)on genetically diabetic KK-Ay mice[J].Biol Pharm Bull,2005;28(5):937-939.
[42]Woo H M,Kang J H,Kawada T,et al.Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes[J].Life Sci,2007;80(10):926-931.
[43]王春彬,高大中,殷跃辉,等.姜黄素对高脂血症兔主动脉NF-κB、VCAM-1、VEGF表达的影响[J].中成药,2007;(8):1127-1129.
[44]Gukovsky I,Reyes CN,Vaquero EC,et al.Curcumin ameliorates ethanol and nonethanol experimental pancreatitis[J].Am J Physiol Gastrointest Liver Physiol,2003;284(1):G85-95.
[45]Natarajan C,Bright JJ.Curcumin inhibits experimental allergic encephalo-myelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes[J].J Immunol,2002;168(12):6506-6513.
[46]Araujo CAC,Leon LL.Biological activities of Curcuma longa L[J].Mem Inst Oswaldo Cruz,2001;96(5):723-728.
[47]鲍华英,陈荣华,黄松明,等.姜黄素抑制脂多糖刺激的系膜细胞增殖及其白细胞介素1β和巨噬细胞趋化蛋白1基因的表达.临床儿科杂志,2003;41(11):822-826.
[48]麦国丰,简燕婷,杨玉捷,等.姜黄素对肠炎大鼠肠黏膜基质金属蛋白酶-9的调控[J].第四军医大学学报,2005;26(14):1257-1260.
[49]王建军,王三萍,熊海金.姜黄素对哮喘大鼠气道炎症与核因子B表达的影响.中国临床康复,2005;9(11):102-104.
[50]UkilA,Maity S,Karmakar S,et al.Curcumin,the major component of food flavour turmeric,reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis[J].Br J Pharmacol,2003;139(2):209-314.
[51]Zhang M,Deng CS,Zheng JJ,et al.Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis[J].Acta Pharmacol Sin,2006;27(8):1071-1077.
[52]Hisanori Y,Kentaro H,Kiyoshi K,et al.Inhibitory effect of curcumin on mammalian phospholipaseD activity.FEBS Letters,1997;417:196-198.
[53]Literat A,Su F,Norwicki M,et al.Regulation of pro-inflammatory cytokine expression by curcumin in hyaline membrane disease(HMD)[J].Life Sci 2001;70(3): 253-267.
[54]鲍华英,陈荣华,潘晓勤,等.姜黄素对脂多糖诱导的系膜细胞单核细胞趋化蛋白1基因及蛋白表达的影响.南京医科大学学报(自然科学版),2003;23(6):536-539.
[55]Tomita M,Holman BJ,Santoro CP.Astrocyte production of the chemokine macrophage inflammatory protein-2 is inhibited by the spice principle curcumin at the level of gene transcription[J].J Neutoinflammation,2005;2(1):8-12.
[56]Molnar V,Garai J.Plant-derived ant-inflammatoty compounds affect MIF tautomerase activitvy[J].Int Immunopharmacol,2005;5(5):849-56.
[57]Lee SL,Huang WJ,Lin WW et al.Preparation and anti-inflammatory activities of diarytheptanoid and diarytheptylamine analogs[J].Bioorg Med Chem,2005;13(22):6175-6181.
[58]Xu G,Huans W,Zhang WM et al.Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis [J].Di Yi Jun Yi Da Xue Xue Bao,2005;25(1):45-52.
[59]Deodhar SD.Preliminary study on antirheumatic activity of curcumin(diferuloylmethane)[J].India JMedRes,1980;71:632-633.
[60]B Lal,AK Kapoor,OP Asthana,et al.Efficacy of curcumin in the management of chronic anterior uveitis.Phyother Res,junel,1999;13(4):318-322.
[61]Reddy AC,Lokesh BR.Effect of Curcumin and eugenol on iron-induced hepatic toxicity in rats[J].Toxicology,1996;107(1):39-44.
[62]SreeJayan,Rao MN.Curcuminoids as potent inhibitors of lipid peroxidation[J].J Pharm Pharmacol,1994;46(12):1013-1019.
[63]Punithavathi D,Venkatesan N,Babu M.Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats[J].Br J Pharmacol,2000;131:169-172.
[64]Okada K,Wangpoengtrakul C,Tanaka T,et al.Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injure in mice.J Nutr,2001;131(8):2090-2095.
[65]Rezzani R,Rodella L,BufToli B,et al.Change in Renel Heme Oxygenase Expression in Cyclosporine A-induced Injury(J.Journal of Histochemistry and Cytochemut}y,2005;53(1):105-112.
[66]Costa MC,Castro I,Neto ALC.Cyclosporin contribute to nephrotoxicity;role for Ca~(2+)and Mg~(2+) ions[J].Dephrol Dial Transplant,2003;18:2262-2268.
[67]Motterlini R,Foresti R,Bassi R,et al.Curoumin,an antioxidant and anti-inflammatory agent,induces heme oxygenese-1 and protects endothelial cells against oxidative stress[J].Free and Medicine,2000,28(8):1303-1312.
[68]刘慎微,付艳红.姜黄素对大鼠环孢素肾毒性的防治作用.中阅药师,2007;10(5):419-422.
[69]龙明智,陈磊磊.姜黄素的药理作用.国外医学中医中药分册,2003;25(5):270-273.
[70]Jones EA,Shahed A,ShoskesDA,eta.Modulation of apoptotic and inflammatory genes by bioflavonoids and angiotensin Ⅱ inhibition in ureteral obstruction[J].Urology,2000;56(2):346-351.
[71]陈华,薛常镐,陈铁辉,等.姜黄及姜黄素对微囊藻粗毒素致急性肝损伤的化学预防作用[J].中国药理学通报,2005;21(12):1517-1519.
[72]Palojokie,Saraste A,Eriksson A,et al.Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction inrats[J].Am J Physiol Heart Circ Physiol,2001;280(6):H2726-H2731.
[73]黄维义,张英,严丽,等.血红素氧合酶-1高表达抗兔心肌缺血再灌注损伤研究.中国现代医学杂志,2006;16(10):1477-1479.
[74]Jeong GS,OH GS,Pae HO,et al.Comparative effects of curcuminoids on endothelial heme oxygenase-1 expression:ortho-methoxy groups are essential to enhance heme oxygenase activity and protection[J].Exp Mol Med,2006;31;38(4):393-400.
[75]Scapagnini G,Colombrita C,Amadio M,et al.Curcumin activates defensive genes and protects neurons against oxidative stress[J].Antioxid Redox Signal,2006;8(3-4):395-403.
[76]Tourkina E,Gooz P,Oates JC,et al.Curcumin-induced apoptosis in scleroderma lung fibroblasts:role of protein kinase cepsilon[J].Am J Respir Cell Mol Biol,2004;31(1):28-35.
[77]Mahmmoud YA.Curcumin modulation of Na~+,K~+-ATPase:phosphoenzyme accumulation,decreased K~+occu-lusion,and inhibition of hydrolytic activity[J].BrJ Pharmacol,2005;145(2):236-241.
[78]Sun M,Chen M,Dawood F,et al.Tumor necrosis factor-αmediates cardiac remodeling and ventricular dysfunction after pressure overload state[J].Circulation,2007;115(11):1398-1403.
[79]陈少伯,李玉明,姜铁明,等.姜黄素对充血性心衰兔心肌肿瘤坏死因子-α表达和心功能的影响[J].中华实用中西医杂志,2004;4(17):1418-1421.
[80]Jones EA,Shahod A,Shoskes DA,et al.Modulation of apoptoticand inflammatory genes by bioflavonoids and angiotensinⅡ inhibitionin ureteral obstruction[J].Urology,2000;56(2):346-351.
[81]刘润侠,党慧敏,段中琪,等.姜黄素防治慢性心力衰竭大鼠左心室胶原网络重 构的实验研究[J].中国中医急症,2006;15(1):70.
[82]Yang X,Thomas DP,Zhang X,et al.Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation[J].Arterioscler Thromb VascBiol,2006;26(1):85-90.
[83]林全,王良兴,周向锋,等.姜黄素防治慢性低O_2高CO_2大鼠肺动脉高压与C-Jun、C-Fos的关系研究[J].中国临床药理学与治疗学,2005;10(10):1118.
[84]徐丙发,吴华璞,祝晓光.姜黄素对大鼠缺血再灌注损伤的保护作用.蚌埠医学院学报,2007;32(60):637-639,封3.
[85]李军,曹红,连庆泉,等.姜黄素减轻沙土鼠海马CA1区脑缺血再灌注损伤与热休克蛋白表达变化的关系[J].温州医学院学报,2007;(4):317-321.
[86]张俊,周文祥,刘晓城,等.姜黄素对大鼠肾系膜细胞结缔组织生长因子表达的影响.华中科技大学学报(医学版),2006;35(1):99-102.
[87]宁勇,刘晓城.姜黄素对糖尿病大鼠肾脏保护作用的研究.湖北中医学院学报,2004;6(1):10-11.
[88]舒建昌,王红利,叶国荣,等.姜黄素治疗肝纤维化及相关细胞因子变化的研究[J].中药材,2007;(11):1421-1425.
[89]Zheng S,Chen A.Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells.Am J Physiol Gastrointest Liver Physiol,2007;292(1):113-123.
[90]舒建昌,何雅军,吕霞,等.姜黄素诱导肝星状细胞凋亡的相关分子机制的初步研究.中华消化杂志,2006;26(11):758-761.
[91]Ha H,Lee HB.Reactive oxygen species and matrix remodelingin diabetic kidney[J].J Am Soc Nephro,2003;14(8 Supp13):S246-249.
[92]李银生,牛建昭,王继峰,等.姜黄素对肺纤维化大鼠肺组织胶原沉积及转化生长因子β1表达的影响[J].中华中医药学刊,2007;25(1):55-57.
[93]汪海慧,成扬.姜黄素药理作用的研究进展.上海中医药大学学报,2007;21(96):73-76.
[94]苏凤菊,曾令兰,李淑莉,等.姜黄素对肝纤维化大鼠瘦素及瘦素受体表达的影响[J].中西医结合肝病杂志,2007;(4):225-226,229.
[95]王浩,付文成,王云满,等.姜黄素及氧化低密度脂蛋白对系膜细胞增殖和凋亡的影响[J].上海医学,2007;(7):145-147.
[96]刘慎微,熊礼佳,付艳红.姜黄素对2型糖尿病大鼠肾脏改变的影响[J].医药导报,2007;26(7):749-753.
[97]Shishir S,Hesham M A,Raymond L,et al.Curcumin(diferuloylmethne) inhibits constitutive NF-κB activation,induces G1/S arrest,suppresses proliferation,and induces apoptosis in mantle cell lymphoma[J].Biochem Pharmacol,2005;70:700-713.
[98]彭文,李琦,付文成,等.姜黄素及OX-LDL对系膜细胞凋亡及FAP-1和bag-1表达的影响[J].上海中医药大学学报,2007;21(4):54-57.
[99]Jungy EM,Limy JH,Lee TJ,et al.Curcumin sensitizes umor necrosis factor related apoptosis inducing ligand TRAIL induced apoptosis through reactive oxygen species ediated upregulation of death receptor5(DR5)[J].Carcinogenesis,2005;26(11):1905-1913.
[100]邓刚,余建华,叶章群,等.姜黄素对雄激素非依赖性前列腺癌细胞PC-3及血管内皮生长因子的影响[J].中华男科学杂志,2008;(2):116-121.
[101]Liu Hong-qi,ChenYan,CuiGuo-hu,et al.Curcumin,a potent anti-tumor reagent,is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation[J].Acta pharmacological Sinica,2005:26(5):603-608.
[102]吕必华,张玲,朱长才,等.姜黄素抑制HepG2细胞HDAC1活性及促进P21-(WAF1/CIP1)表达的研究[J].中国中药杂志,2007;(19):2051-5055.
[103]刘波,白庆咸,陈协群,等.姜黄素对人多发性骨髓瘤细胞表达Survivin、Bcl-2、Bax的影响[J].中国实验血液学杂志,2007:(4):762-766.
[104]Moragoda L,Jaszewski R,Majumdar AP.Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells[J].Anticancer Res,2001;21(2A):873-878.
[105]Park,SD.Zedoariae rihzoma and curcumin inhibits platelet-der Vedgrowth factorinduced proliferation of human hepatic mypfibroblasts[J].Int Immunopharmacol,2005;5:555-569.
[106]梁斌,·黄美健,丁志山.脱甲氧基姜黄素对血管生成影响的实验研究[J].浙江中西医结合杂志,2008;(2):69-70.
[107]孙军,李岩.姜黄素对人肝癌细胞BEL-7402中HIF-1表达的影响[J].中国药理学通报,2006;22(11):1379-1383.
[108]Yang XP,Thoams P,Zhang XC,et al.Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation[J].Arterioscler ThrombVasc Biol,2006;26(1):85-90.
[109]Anuchapreeda S,Leechanachai P,Smith MM,et al.Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells[J].Biochem Pharmacol,2002;64
[110]Tang XQ,Bi H,Feng JQ,et al.Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR[J].Acta Pharmacol Sin,2005;26(8):1009-1016.
[111]英焕春,吕靖,张淑兰,等.姜黄素对卵巢癌耐药细胞株COC1/DDP的增敏作 用及其机制的研究[J].广西医科大学学报,2007;(3):361-364..
[112]高凤兰,李维山,任亮,等.姜黄素对马利兰耐药HL-60细胞生长的影响[J].中国现代医药杂志,2007;9(6):35-37.
[113]Sanjay Kumar,Upma Narain,Snehiata Tripathi,et al.Syntheses of curcumin bioconjugates and study of their antibacterial activities against β-lactanlase-producing microorganisms[J].Bioconjugate Chem,2001;12:464-469.
[114]胡小军,李凤侠.姜黄油抑菌作用的研究[J].食品研究与开发,2006;27(5):30-31.
[115]Koide T.姜黄素的体外杀利什曼原虫作用[英].Biol Pharm Bull,2002;25(1):131-133.
[116]Dalavaikodihalli NN,ViswanathanAN,Palakkod G,et al.Curcumin Artemisinin combination therapyfor malaria[J].Antimicrob Agents Chemother,2006;50(5):1859-1860.
[117]张永强,丁伟,赵志模,等.姜黄对朱砂叶螨生物活性研究[J].植物保护学报,2004;31(4):390-394.
[118]Shishir,MA Hesham,L Raymond,et al.Biochemical Pharmacology,2005;70(5):700-713.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |